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21 Abstract 
In this project the role of two relatively unknown genes; RalGDS-like1 (RGL1) and Cip-interacting 
Zinc finger protein 1 (Ciz1) were investigated. RGL1 is a proposed Ras effector protein, which has 
been suggested to be involved in regulation of cell proliferation and differentiation. Ciz1 has been 
suggested to have a role as a transcription or replication factor, due to three zinc finger domains, but 
the protein also contains two polyglutamine domains, which are normally associated with 
neurodegenerative diseases.  
Various splice forms of the two genes were investigated by PCR on cDNA for possible 
upregulation on mRNA level in hippocampal tissue pooled from four Alzheimer’s Disease (AD) 
patients. Further PCR studies were carried out, examining the mRNA levels in various tissues and a 
range of cancer cell lines. The cellular localization of the protein isoforms were also investigated, 
by immunofluorescence staining of transfected N2A neuroblastoma cells, as well as fractionation of 
the cells by use of different detergents, resulting in a soluble fraction, two fractions of proteins 
bound to chromatin, and a fraction of proteins bound to the nuclear matrix.  
The experiments performed in this project showed that two RGL1 splice forms appear 
downregulated in AD tissue, and that RGL1 seems to induce differentiation in neuroblastoma. One 
Ciz1 splice form appeared slightly upregulated in AD tissue, and expression of different Ciz1 
variants showed a dramatic variance in appearance and cellular localization. Extraction of Ciz1 
proteins by different detergents showed that Ciz1 binds to chromatin and nuclear matrix.  
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52 Introduction 
2.1 Alzheimer’s Disease 
Alzheimer’s Disease (AD) is the most common cause of dementia, and like many other 
neurodegenerative diseases still remains untreatable. This is partly due to the deficiency of a 
complete diagnostics; only a post-mortem autopsy can give a definitive diagnosis. AD is normally 
divided in two types; sporadic, with a clinical appearance after 65 years and familial, which can 
appear as early as 40-50 years. Both types are characterized by severe impairment of memory, with 
later, additional deficits in other cognitive functions, such as language. Post-mortem autopsies 
report neuropathology changes in various regions of the brain, and in particular the hippocampus, 
which has been identified to play an important role in memory.  
Fig. 2-1 (A) Anatomy of the 
human brain with the 
subsections of hippocampus. 
Modified from 
www.gaudiyadiscussions.com 
(B) The subsections of 
hippocampus, where CA1 is 
the most affected region in 
AD. www.bio.davidsen.edu 
(C) Plaques and (D) tangles in 
AD tissue. Modified from 
(Gotz et al., 2006). 
6The first region to be affected in AD is the CA1 region of hippocampus (Fig. 2-1 A, B) (West et al.,
1994), but also the entorhinal cortex and specifically cholinergic neurons1 in the basal forebrain, 
which is positioned close to hippocampus, are affected early. Later in the clinical process the 
frontal, temporal and parietal cortex is also affected, reviewed in (Nussbaum and Ellis, 
2003;Twamley et al., 2006). In the afflicted regions of AD brains, severe neuron and synapse loss, 
extracellular senile plaques (Fig. 2-1 C) and insoluble neurofibrillary tangles (NFTs) (Fig. 2-1 D) 
are found. The tangles have been shown to consist of hyperphosphorylated Tau protein, which is a 
microtubule-associated protein that normally stabilizes microtubules that make up the cellular 
cytoskeleton. If the Tau protein is not dephosphorylated it cannot bind to the microtubules, and 
instead it forms into tangles, reviewed in (Kar et al., 2004). The plaques consist mainly of -
amyloid deposits, but various other proteins have also been found to localize in the plaques, e.g 
Tau; Apolipoprotein E (APOE), which is an important ligand in receptor-mediated lipoprotein 
uptake, and have been determined as an important factor in the probability of developing AD. 
Studies have discovered that the APOE-4 allele has a dose-related effect on the risk of developing 
AD. Possessing one allele of the APOE-4 gene results in a 2-5 times risk of developing AD, while 
two alleles increases the risk to more than 5 times. In contrast the expression of the APOE-2 allele 
appears to have a protective effect, reviewed in (Kar et al., 2004); prion proteins (PrPs), proteins are 
associated with diseases such as Creutzfeld-Jacob disease and Bovine Spongiform Encephalopathy 
(BSE), where a modification to the normal PrP protein results in a protease resistant form, which 
accumulates in the brain. The pathological features of these diseases include spongiform 
morphology and like AD, amyloid plaques (Prusiner, 1996;Schwarze-Eicker et al., 2005).  
Studies of patients with the familiar type of AD have furthermore shown three genes to be involved 
in AD. Missense mutations which alter a single amino acid have been found in the gene encoding 
amyloid precursor protein (APP), and presenilin 1 and 2. APP is a transmembrane protein placed in 
the inner cell membrane, which is suggested to have a role in neuron-glia cell adhesion, which 
could make APP an important factor in brain development, reviewed in (Gralle and Ferreira, 2007). 
It is cleaved by - and -Secretase, which releases the extracellular part of the protein, an 
approximately 40 aa peptide, -amyloid into the cytosol, where it aggregates into senile plaques. 
Presenilin 1 and 2 are transmembrane proteins, which associate with three other proteins to form the 
1 Cholinergic neurons are neurons that use acetylcholine as neurotransmitter.  
7-secretase complex. The mutation in APP found in AD patients, causes an upregulation of the 
amount of -amyloid (Gandy, 2005), which leads to an accumulation of -amyloid. Similarly the 
mutations found in presenilins cause a higher activity of the -secretase (De Strooper et al., 1998), 
which again causes an accumulation of -amyloid.  
Patients diagnosed with sporadic AD do not however have a mutation in the APP or presenilin 
genes, so what causes the -amyloid deposits here is not known. So besides inherited mutations, the 
basis for developing AD is not well understood. Therefore the search for genes involved in the 
molecular processes continues. A number of genes have recently been shown to be associated with 
AD, by having an altered expression in AD tissue. For example glial fibrillary acidic protein 
(GFAP) which is an intermediate filament protein found in astrocytes in the central nervous system. 
If the cells are injured, like in AD, they become reactive, termed reactive gliosis, and start 
producing more GFAP (Eng et al., 2000). Therefore an upregulation of GFAP on mRNA level has 
been found in AD (Diedrich et al., 1987). Also a relatively unknown protein N-myc downstream 
regulated gene 2 (NDRG2), has been shown to be upregulated in AD, both on mRNA and protein 
level (Mitchelmore et al., 2004).
8The more we learn about the molecular processes and genes involved in AD, the closer we get to a 
possible treatment of the disease. Therefore the aim of this project was to find new genes involved 
in AD. This search of new genes was based on a slot blot performed by (Mitchelmore unpublished), 
testing a variety of genes for possible altered mRNA expression in AD tissue. The blot showed a 
possible upregulation of Ciz, RGL1 and Ephrin A3 (Fig. 2-2), which were selected to be further 
investigated for a possible role in AD. The following sections will introduce the genes and the 
proposed functions of the gene products.  
Fig. 2-2. Slot blot by (Mitchelmore 
unpublished). Plasmid DNA 
containing cDNA for the possible 
AD associated genes, as well as 
GFAP which is upregulated in AD, 
and GAPDH for normalization of 
the cDNA level, were blotted onto 
a membrane.  One half was 
probed with radioactive labeled 
cDNA from AD hippocampus and 
the other from normal 
hippocampus.  
92.2 Ciz1
Ciz1, Cip1 interacting zinc finger protein 1 is a relatively unknown gene, located on chromosome 
9q34.1, and is composed of 18 exons. The gene is subjected to alternative splicing, and produces 
mRNA transcripts of approximately 2.7 to 3 kbp. The gene products weigh approx. 100 kDa, 
having three Zinc-fingers in the C-terminal end and two glutamine-rich domains in the N terminal 
end (Fig. 2-3). The first glutamine domain consists of 31 glutamines, only divided by a few 
Leucines, whereas the second, larger domain contains approximately 72 glutamines, but separated 
by several other amino acids.  
VAKQGAGCSEKDKKWFLLPSSLPHPAARASPLAALRTDGGGSP
RATMFSQQQQQQLQQQQQQLQQLQQQQLQQQQLQQQQLLQL
QQLLQQSPPQAPLPMAVSRGLPPQQPQQPLLNLQGTNSASLLN
GSMLQRALLLQQLQGLDQFAMPPATYDTAGLTMPTATLGNLR
GYGMASPGLAAPSLTPPQLATPNLQQFFPQATRQSLLGPPPVGV
PMNPSQFNLSGRNPQKQARTSSSTTPNRKDSSSQTMPVEDKSD
PPEGSEEAAEPRMDTPEDQDLPPCPEDIAKEKRTPAPEPEPCEAS
ELPAKRLRSSEEPTEKEPPGQLQVKAQPQARMTVPKQTQTPDL
LPEALEAQVLPRFQPRVLQVQAQVQSQTQPRIPSTDTQVQPKL
QKQAQTQTSPEHLVLQQKQVQPQLQQEAEPQKQVQPQVQPQA
HSQGPRQVQLQQEAEPLKQVQPQVQPQAHSQPPRQVQLQLQK
QVQTQTYPQVHTQAQPSVQPQEHPPAQVSVQPPEQTHEQPHTQ
PQVSLLAPEQTPVVVHVCGLEMPPDAVEAGGGMEKTLPEPVG
TQVSMEEIQNESACGLDVGECENRAREMPGVWGAGGSLKVTI
LQSSDSRAFSTVPLTPVPRPSDSVSSTPAATSTPSKQALQFFCYI
CKASCSSQQEFQDHMSEPQHQQRLGEIQHMSQACLLSLLPVPR
DVLETEDEEPPPRRWCNTCQLYYMGDLIQHRRTQDHKIAKQSL
RPFCTVCNRYFKTPRKFVEHVKSQGHKDKAKELKSLEKEIAGQ
DEDHFITVDAVGCFEGDEEEEEDDEDEEEIEVEEELCKQVRSRD
ISREEWKGSETYSPNTAYGVDFLVPVMGYICRICHKFYHSNSG
AQLSHCKSLGHFENLQKYKAAKNPSPTTRPVSRRCAINARNAL
TALFTSSGRPPSQPNTQDKTPSKVTARPSQPPLPRRSTRLKRSRR
DLPVPGLPGSRSANAF
Fig. 2-3. The amino acid sequence of full length Ciz1 protein, and illustration of Ciz1 domains; two 
glutamine rich domains and three zinc fingers. 
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2.2.1 Ciz1 as a transcription factor
Zinc fingers are motifs which are able to bind double stranded DNA, and are therefore often found 
in DNA interacting proteins like transcription factors (TF). The zinc finger motifs in the C-terminal 
part of Ciz1, could suggest a possible transcriptional activity, but a reporter assay using GAL4-
constructs performed by (Mitsui et al., 1999) did not indicate that.
An immunoprecipitation using random oligo nucleotides performed by (Warder and Keherly, 2003) 
did however show that Ciz1 is able to bind DNA, and more specific the consensus sequence 
“ARYSR(0-2)YYAC”2. Searching a TF binding site database, they found this sequence to match 
four known binding sites: Cdx-1 (an intestine-specific transcription regulator, which has been 
associated with development and invasiveness of colorectal cancer (Mallo et al., 1998)); GATA-1 
(a major TF regulating erythroid development (Pevny et al., 1995), which has also been shown to 
directly regulate cyclin D1 expression, and thereby influence the G1 phase of the cell cycle 
regulated by the cyclin D1/CDK4 complex (Muntean et al., 2007)); HSF (a transcription regulator 
of mammalian heat shock genes (Fernandes et al., 1994)); c-Ets-1 (a TF regulator, which have been 
shown to be overexpressed in neuroblastomas, and the level of expression also correlates highly 
with the invasiveness of breast tumors and colorectal carcinomas (Qiao et al., 2007)).
Whether or not Ciz1 functions as a transcription factor remains undisclosed, but if it binds to these 
TF binding sites, it could mean that Ciz1 e.g. by blocking the TF-sites, is involved in regulation of 
the cell cycle and cancer development.  
2.2.2 Polyglutamine domains are associated with neurodegenerative diseases
The glutamine-rich (polyQ) domains are particularly interesting, since they have been found in 
proteins associated with a number of neurodegenerative diseases e.g. Huntington Disease, various 
forms of atrophic diseases, and also AD. These proteins all have a region of CAG-repeats, which 
translates into a long stretch of glutamines. Leaving out this (CAG)n domain, the genes do not seem 
to have anything in common, except for the fact that they are all highly expressed in the central 
nervous system and peripheral tissues (Landles and Bates, 2004).  
2 R=G/A, Y=T/C, S=G/C. 
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In Huntington Disease (HD) mutations in the Huntingtin gene (Htt) have given rise to alleles with 
longer polyglutamine domains, which cause the proteins to misfold. Carriers of these alleles 
develop HD, which phenotype is insoluble aggregates in the brain, causing neurodegeneration. The 
number of CAG repeats has been shown to be the determinant of whether an individual develops 
HD; Fewer than 35 repeats does not cause HD, 36-39 repeats gives an increased risk, and more than 
39 repeats will cause HD, reviewed in (Bates, 2003).  
AD has also been associated with polyQ proteins, where a coherence between the Androgen 
receptor allele with less than 20 CAG repeats, and development of AD in men was found (Lehmann 
et al., 2003). The Androgen receptor is furthermore involved in spinal and bulbar muscular atrophy 
or Kennedy’s Disease, where an allele of the Androgen Receptor with 40-62 CAG repeats 
(compared to 14-32 repeats in the normal allele), causes neurodegenerative aggregates in men 
(Adachi et al., 2005). Again the number of CAG repeats is determinative for development of the 
neurodegenerative disease. In addition, the TATA binding protein (TBP) which contains alleles 
with 25-42 CAG repeats, have been shown to form aggregates that localize in the NFT of AD brains 
(Reid et al., 2004). These findings seem to indicate that polyQ proteins could have a role in AD, 
and even though Ciz1 only have relatively few CAG repeats, it still remains possible that Ciz1 is 
involved in aggregate formation. 
Immunofluorescence staining of Ciz1 transfected U2-OS cells performed by (Mitsui et al., 1999) 
have however shown that Ciz1 forms aggregates in the cytoplasm but only when the entire reading 
frame is expressed. They did not find the same speckled pattern when expressing constructs 
containing only the 5’ or 3’ end of Ciz1 (Fig. 2-4), though this seems a little ambitious to conclude 
from these pictures. 
The general theory is though, that the a
observed, but extra nuclear polyQ prot
signaling pathways (Benn et al., 2005)
involved in AD, has not been determin
contributing factor in AD. 
2.2.3 Ciz1 involvement in AD throug
Estrogen is an important regulator of g
which interacts with estrogen response
interacting with DNA-binding transcri
development of AD. A study of approx
late-onset sporadic AD and 200 health
particular ER -allele and developing A
shown to localize in cholinergic neuron
are affected early in AD, and Estrogen
of APP (Jaffe et al., 1994).
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Recently Ciz1 has been shown to be an estrogen-inducible gene, having multiple possible EREs 
upstream of exon 1 and 2 (Fig. 2-5), and increased levels of Ciz1 mRNA was found in estrogen-
stimulated MCF-7 and ZR-75 breast cancer cells. In addition induction of estrogen also resulted in 
increased levels of Ciz1 mRNA in ER-positive cells, but not in ER-negative cells, which further 
demonstrates that the Ciz1 gene is regulated through the ER. Ciz1 was also found to colocalize with 
ER in ZR-75 breast cancer cells and in an immunoprecipitation Ciz1 has also been shown to bind 
ER, by interacting through the second Glutamine-rich domain. A Luciferase-assay has furthermore 
showed that Ciz1 acts as a coactivator of ER (den Hollander et al., 2006). 
All these results seem to indicate that Ciz1 could be involved in the Estrogen pathway and perhaps 
through this also in the development of AD. 
2.2.4 Ciz1 as a cell cycle regulator
Ciz1 was first isolated and characterized by (Mitsui et al., 1999), by a yeast two hybrid screening of 
possible  cyclin E/p21cip1/WAF1 interaction partners and they showed that Ciz1 interacted with 
p21cip1/WAF1, hence the name. Since p21 is a major factor in controlling onset of the S phase (Fig. 
2-6), by inhibiting cyclin-cdk2 complexes and PCNA, Ciz1 could be an important regulator of cell 
cycle. 
Fig. 2-6. Illustration of the 
cell cycle with regulators. 
Cyclin dependent kinases 
(CDKs) regulate the 
transition between the 
different cycles, and CDK 
inhibitors act to block these 
transitions. p21 functions as 
an inhibitor of CDK2/cyclin 
E, which controls the onset of 
S phase. (www.breast-cancer-
research.com) 
Therefore (Mitsui et al., 1999) investigated the cellular localization of Flag-tagged Ciz1, as well as 
possible colocalization of p21 and Ciz1. Expression of Ciz1 alone in U2-OS cells showed it to be 
present as speckles in the nucleus, whereas Myc-tagged p21 was also present in the nucleus, but as 
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a diffused pattern. Coexpression of Ciz1 and p21 changed the pattern of both, to being colocalized 
in inclusion bodies in the cytoplasm, as well as Ciz1 being present diffusely throughout the cell. 
The inclusion bodies could very likely be caused by their ability to bind to each other. Supporting 
this theory, murine Ciz1 has been shown to stimulate DNA replication in NIH 3T3 cells. An 
experiment on p21Cip1 null cells did however also show that Ciz1 promote DNA replication 
(Coverley et al., 2005), which indicates that Ciz1 regulates the cell cycle by both interacting with 
p21, but also through a more direct way. 
Overexpression of Ciz1 has also been shown to promote cyclin D1 expression (den Hollander et al.,
2006), which participates in the cyclin D1/CDK4 complex. This corresponds with the mentioned, 
proposed Ciz1 transcription factor binding site GATA-1, which regulates D1 expression, but it 
could however also be an effect of Ciz1 affecting estrogen, which has been confirmed to lead to an 
increased cyclin D1 production (Prall et al., 1997). 
2.2.5 Ciz1 inhibits cell differentiation
Studies have shown that many cell cycle regulators also have important roles in the differentiation 
process. For instance, inhibition of CDK2 and cdc2 which regulate entrance to the S-phase, induces 
differentiation of PC12 cells (Ohnuma et al., 2001). The discussed role of Ciz1 as a cell cycle 
regulator could therefore also suggest that Ciz1 is involved in cell differentiation. However, p21, 
which Ciz1 has been suggested to inhibit, has been found to be required for cell differentiation in 
oligodendrocytes (Zezula, 2001), and neurite outgrowth and branching is promoted in hippocampal 
neurons, when p21 is highly expressed (Tanaka et al., 2002). Assuming that Ciz1 functions as an 
inhibitor of p21, Ciz1 could thereby have a role in inhibition of differentiation, by promoting entry 
into S-phase.
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2.2.6 Tissue specificity of Ciz1
In order to determine the role of Ciz1, and thereby its possible involvement in AD, it is helpful to 
know in which tissues Ciz1 is expressed. (Warder and Keherly, 2003) examined Ciz1 mRNA levels 
in multiple tissues, and found a relatively high level in the brain. The highest level was furthermore 
found in the cerebellum. These results indicate that Ciz1 could have an important role in the brain.  
Fig. 2-7. Ciz1 expression in human 
tissues. Northern blot of total RNA, 
was run on a gel, blotted onto a nylon 
membrane and hybridized to a Ciz1 
specific probe. 
Adapted and modified from (Warder 
and Keherly, 2003). 
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2.2.7 Ciz1 splice forms
The Ciz1 gene is regulated by alternative splicing, resulting in various Ciz1 transcripts. (Coverley et 
al., 2005) amplify the importance of investigating different splice forms of Ciz1, due to the splice 
variations in mouse Ciz1 closely resemble the ones found in human Ciz1. They furthermore state 
that some of these are identical on amino acid level, which could suggest that the isoforms of Ciz1 
have a significant, functional difference. 
One splice variant has an alternative first exon (2 instead of 1), but since the start codon is localized 
in exon 3, the reading frame is not affected. The more interesting variants have alternative splice 
sites within exon 9, producing three different transcripts.  
Fig. 2-8. Three Ciz1 splice forms were chosen to be further investigated; a full length variant (Ciz F), 
a splice variant lacking 84 bp of exon 9 (Ciz M) and one lacking 168 bp (Ciz L) which includes the 
region lacking in Ciz M (underlined region).  
The full length transcript (Ciz F) as well as two variants lacking a part of exon 9; Ciz M, which 
lacks 84 bp, and Ciz L which lacks 168 bp (which includes the region missing in Ciz M) (Fig. 2-8), 
was chosen to be examined in this project. Both variants have an interrupted second glutamine rich 
domain of the translated protein, but the frame does not shift, so the only difference between the 
variants is the length of this glutamine-rich region.   
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2.3 RGL1 
RGL1, Ral GDS (guanine nucleotide dissociations stimulator) like 1 is located on chromosome 
1q25.3, and consists of 20 known exons. It is regulated by alternative splicing, producing transcripts 
of approximately 5 kbp. The gene products are proteins of approx. 85 kDa, containing three 
domains; a RasGEF_N, a RasGEF and a RalGDS_RA domain (Fig. 2-9). From these domains it has 
been suggested that RGL1 functions as a guanine exchange factor, but the precise role of RGL1 has 
not been fully determined. 
The RasGEF (Ras Guanine exchange factor) and RasGEF_N (N-terminal) domains are often found 
together (RasGEF_N N-terminal to RasGEF) in exchange factors and activating proteins for Ras-
like small GTPases. The RalGDS_RA (Ras activating) domain is found in the C-terminal end of 
proteins that are able to bind Ras, e.g. RalGDS and Ras-related GTPases Ral and Rap1.  
2.3.1 RGL1 is a possible Ras effector protein
Ras is a membrane bound protein, anchored to the cytoplasmic site of the outer cell membrane. 
There exist three known isoforms of Ras (H-ras, K-ras and N-ras), which all have a function in 
helping to broadcast signals from the cell surface to the nucleus. One important function is in the 
transfer of signals, upon binding of the neutrophin nerve growth factor (NGF) to the tyrosine kinase 
A (trkA) receptor. This occurs through a phosphorylation cascade of various downstream effectors, 
referred to as the Ras-MAP kinase cascade (Fig. 2-10). The cascade ends by activating ERK-1, 
which stimulates cell proliferation or differentiation by altering both protein activity in the cytosol 
and also gene expression, by translocating to the nucleus and phosphorylating e.g. TFs, reviewed in 
(Seger and Krebs, 1995). Neurons rely on the constant stimulation of NGF to survive, but increased 
stimulation of NGF has been shown to stimulate outgrowth of neurites, reviewed in (Blood, 1972).  
Fig. 2-9.  Illustration of the two GTP-exhange factor domains; RasGEFN, RasGEF and the ras 
binding domain; RalGDS_RA. 
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Fig. 2-10. The Ras-MAP kinase 
pathway. The nerve growth factor 
(NGF) binds to the Trk A receptor 
and activates it. The signal is 
hereafter broadcasted through 
various downstream effectors 
including Ras, and terminates in 
altering of transcription. (Nicholls 
et al., 2001) 
Ras is a GTP binding protein which is active when bound to GTP and inactive when bound to GDP. 
Guanine nucleotide exchange factors (GEFs) function to stimulate GDP to GTP exchange, which 
thereby acts as Ras activators. GTPase activating proteins (GAPs) promote hydrolysis of GTP-Ras, 
to GDP-Ras which thereby inactivates Ras. Mutations in the Ras gene have been found to create 
oncogenes, which results in hyperactive gene products, that are resistant to GAPs, and thereby can 
promote development of cancer. 
The GEF and RA domains indicate that RGL1 functions as a Ras activator, which means that RGL1 
could promote cell proliferation or differentiation. This corresponds well with experiments showing 
RGL1 to bind Ras through the RalGDS_RA domain (Koyama et al., 1996). Another experiment did 
however show that RGL1 reduces maturation of Xenopus oocytes (Koyama et al., 1996), which is 
regulated through the MAP kinase (Kosako et al., 1994), showing that RGL1 maybe is an inhibitor 
of Ras. The Ras proteins have however been shown to be involved in many different signaling 
pathway, leading to e.g. growth stimulation of fibroblast cells and also the opposite; growth 
inhibition of epithelial cells, reviewed in (Satoh et al., 1992). Therefore the role of RGL1 is still 
unclear, but it could turn out to be quite important, since Ras mediated signal transduction is a 
19
major factor in many human cells, and mutations in Ras often are associated with many human 
cancers (Barbacid, 1987). 
The Ras pathways are however composed of multiple proteins, having Ras interacting domains, or 
other similar domains that allows them to bind together. Therefore it is also possible that RGL1 
interacts with Ras effector proteins, instead of directly with Ras, or both. For an example, (Ikeda et 
al., 1995) found RGL1 to bind Rap1, which is a Ras effector protein. Therefore they postulate that 
the role of RGL1 could be to mediate the signal from Ras to Rap1. They furthermore found that 
binding of Rap1 to Ras, inhibited the binding of RGL. Therefore RGL1and Rap1 could also 
function as competitive regulators of Ras.  
2.3.2 The RalGDS family
RGL1 has 50% amino acid sequence homology to RalGDS, and is thereby considered a member of 
the RalGDS family. A hypothesis proposed by Hofer et al states that RalGDS possibly acts as a 
mediator of signals from Ras to Ral, which is a relatively unknown protein associated to the 
membrane (Hofer et al., 1994). Raf-1 was also found to compete for binding to Ras with RalGDS 
(Hofer et al., 1994). Since RGL1 has high homology with RalGDS, including the Ras interacting 
domain, it is possible that RGL1 is also able to mediate signals from Ras to Ral. Recently two new 
members of the RalGDS family have been found; RGL2 (or Rlf) and RGL3 (or RPM). RGL2 has 
approximately 40% sequence homology with RGL1, and 45% with RGL3 on the amino acid level 
(see Appendix VI: Alignment of RalGDS family proteins), and they do also have the Ras-
interacting domain, as well as the RasGEF domains. Both gene products are relatively unknown, 
but are speculated to function as Ras effector proteins like RGL1.  
RGL2 has been found to bind Ras and Rap1 through their effector domain, but only the active GTP-
bound form of Ras, and a coexpression of RGL2 and oncogene Ras in NIH 3T3 cells, resulted in an 
inhibition of Ras mediated transcription activation (Peterson et al., 1996). Therefore RGL2 is 
suggested to be a Ras or Rap1 effector. RGL2 has further been shown to induce transcription of the 
c-fos promoter, independent of the Ras-MAP pathway (Wolthuis et al., 1997). 
RGL3 has been suggested to be a signaling mediator downstream of Rit and Ras, since murine 
RGL3 (approximately 80% homology to human RGL3) has been shown to bind the GTP-bound 
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state of both. Furthermore coexpresion of murine RGL3 and ongogene Ras in HEK293 cells, 
resulted in an increase of GTP-bound Ral, whereas the same experiment with RGL3 lacking the 
Ras-binding domain, did not stimulate Ral-GTP levels (Shao and Andres, 2000). This could 
indicate that RGL3 forms a complex with Ras, to activate the Ras effector protein Ral. 
Cotransfection of HEK293 cells with an Elk-1 dependent luciferase reporter gene, Ras and human 
RGL3, showed that RGL3 functions as an inhibitor of Elk-1 (Ehrhardt et al., 2001), and thereby has 
a role as transcription inhibitor. Furthermore a recent publication showed that murine RGL3, 
associate with an actin-binding protein profilin II, to suppress cell spreading in NIH 3T3 cells (Xu 
et al., 2007).
Whether or not RGL1 are involved in the same pathways as RalGDS, RGL2 or RGL3 is not certain, 
but the elucidation of the role of other RalGDS proteins, could maybe assist in determining the role 
of RGL1, since the domains are so well conserved.  
2.3.3 Conservation between species
Looking at the conservation between human RGL1 and mouse RGL1, a high homology is found; 
89% on nucleotide level and 94% on amino acid level. Furthermore most of the dissimilarities 
between the sequences are found in the interdomain regions. This seems to indicate that the function 
of RGL1 is very important.  
2.3.4 Tissue specificity of RGL1 
A northern blot performed by (Sood et al., 2000) showed RGL1 to be present in all tissues, though 
it is hard to compare the bands since no loading control is shown, and different splice variants 
cannot be identified (Fig. 2-11).  
Fig. 2-11. Northern blot of 
RGL1 expression in a 
range of tissues. (Sood et 
al., 2000). 
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2.3.5 RGL1 splice forms
Given the possible important roles in cell cycle regulation, the fragmentary knowledge of RGL1 is 
inadequate. Thus many experiments still remain to be conducted in order to determine the role of 
RGL1. Two splice forms differing in the 5’ end, and having different startsites were chosen to be 
examined in this project; RGL A which has a startcodon in exon 3, and RGL C which has two 
alternative first exons, with a startcodon in exon 2 (see Appendix V: cDNA sequences). The 
translated proteins from these splice forms do however both have the three domains; RasGEF_N, 
RasGEF and RalGDS_RA, since exon 5 codes for the first domain, RasGEF.  
Fig. 2-12. These two RGL1 splice forms were chosen to be further examined in this project. RGL A 
has a start codon in exon 3, where RGL C has two alternative first exons; 1 and 2, with a start codon 
in exon 2. 
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The lamination of hippocampus has been found to occur through very specific axonal paths. 
Pyramidal cell axons form the stratum pyramidale (Fig. 2-14 A, p), which is divided into cornu 
ammonis (CA) 1, 3 and the subiculum (SUB), and various other axonal paths project from specific 
points and progress through highly controlled pathways.  
A B
Fig. 2-14 (A) The axonal growth pathways in hippocampus and entorhinal cortex (EC) during 
development of the brain.  Axons from the entorhinal cortex enter the hippocampus through a 
perforant pathway in the dentate gyrus (dg) and the cornu ammonis (CA) 1 region through alvear 
pathway and mossy fibers connect dg with the CA3 region, as well as CA3 with CA1. (Skutella and 
Nitsch, 2001). (B) In situ hybridization of Ephrin A3 mRNA in rat embryo sections showed expression 
in cortex, CA1 and CA3 regions, as well as dentate gyrus (Stein et al., 1999).
In situ hybridization of Ephrin A3 mRNA in a horizontal section of a rat embryo during brain 
development shows Ephrin A3 to be present in particular layers of hippocampus; cortex, CA1, CA3 
and the granular layer in dg (Fig. 2-14 B), which corresponds with the pyramidal cell layers. Ephrin 
A3 has also been shown to inhibit neurite outgrowth from a study of entorhinal explants cultivated 
on top of Ephrin A3 expressing cells, whereas the neuritogenesis was not affected in explants 
cultivated on Ephrin A5 expressing cells (Stein et al., 1999). These observations indicate that 
Ephrin A3 and A5 are important factors in the development of the pyramidal cell layer of 
hippocampus, where Ephrin A3 function to repel the migrating axon and A5 attract the axon, to 
form the laminar structure.  
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2.5.2 Ephrin A3 involvement in AD
Neurons are not normally capable of proliferation in the adult brain, and neuron loss is therefore 
considered irreversible. Some experiments have however shown neural stem cells to reside in the 
granular layer of dg, which can differentiate and extend axons into the CA3 region (Gage and van 
Praag, 2002). The possibility of Ephrin A3 to be upregulated in the human brain because of 
regeneration of AD afflicted neurons could therefore be caused from elevated differentiation in dg, 
as an attempt to compensate for the damaged neurons.  
Ephrin-Eph receptor interactions have also been proposed to have a role in inflammation (Ivanov 
and Romanovsky, 2006), and the expression of Ephrin A3 in AD tissue could therefore also be 
related to inflammation processes in the AD afflicted neurons.  
2.5.3 Tissue specificity of Ephrin A3 and involvement in tumor angiogenesis
Though the highest expression of Ephrin A3 has been found in brain tissue, Ephrin-Eph receptor 
interactions have also been found to control other cell-cell interactions e.g. in breast epithelial cells. 
Experiments have further shown various Eph receptors and Ephrins to be upregulated in several 
types of cancers, and some experiments point to a role of Eph receptors and Ephrins in angiogenesis 
in tumorgenesis. Ephrin A3 has furthermore been shown to be 26 fold upregulated in squamous cell 
lung carcinoma at mRNA level, though their study was only based on samples from two cancerous 
tissues and five normal tissues (Cheng et al., 2002;Hafner et al., 2004).  
25
2.5.4 Ephrin A3 splice forms
Since Ephrin A3 is likely to have an important role in hippocampus, which is the first to be affected 
in AD, it is possible that Ephrin A3 is upregulated in AD. The upregulation could be caused by 
axonal sprouting from the dentate gyrus, an inflammation related process in CA1 and 3, or an entire 
different involvement.  
For examination, two splice forms of Ephrin A3 were chosen (Fig. 2-15); the full length variant and 
an alternative spliced variant which was found during preliminary experiments, which has only 
been predicted in Rattus norvegicus. This variant is lacking exon 4, which comprises approximately 
200 bp. The absent exon 4 does not produce frameshift, or result in an interruption of the ephrin 
domain, since the sequence which translates into the domain is located in exon 1 to 3.  
Fig. 2-15. Exon structure of the full length 
transcript of Ephrin A3; Ephrin F, and an 
alternatively spliced variant lacking exon 4. 
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2.6 Motivation
As previously described, the aim of this project is to investigate the role of RGL1, Ciz1 and Ephrin 
A3, since their function is not very well defined. Preliminary experiments have pointed to a possible 
association with AD, and also a role in cancer development has been suggested for all genes. The 
elucidation of their role in normal cells is however also very important for the understanding of 
what goes wrong in AD, and thereby determining a possible way of treating the disease. Therefore 
experiments were designed to examine both possible altered expression in AD and cancerous 
tissues, but also to investigate the normal function of the gene products in the cell.  
The aims of this project are to: 
- Investigate a possible upregulation of RGL1, Ciz1 and Ephrin A3 on mRNA level in AD 
afflicted hippocampal tissue, compared to normal hippocampal tissue.  
- Examine mRNA levels of the genes in selected human tissues, to reveal possible tissue 
specificity of the genes. 
- Examine mRNA levels of the genes in various cancer cell lines, to get an indication of 
possible involvement in cancer.  
- Compare the results of selected splice forms of the genes, which could help to identify the 
function of specific coding regions of the gene.  
- Express the various splice forms in neuroblastoma cells to study their potential effect on 
proliferation, apoptosis or differentiation. 
- Identify the possible binding of Ciz1 to chromatin or the nuclear matrix, by separating the 
selected components of the cells into different fractions.  
- Examine the sub-cellular localization of the various protein isoforms in the cells, by 
immunofluorescence staining.   
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3 Materials and Methods 
3.1 Materials from Mitchelmore et al.  
Total RNA from CA1 Hippocampal region of four Late Onset AD patients was obtained from John 
Hopkins University Alzheimers Disease research Center. Poly (A+) mRNA from the total RNA was 
isolated, transcribed to cDNA, and the RNA strand removed. Same procedure was performed on 
normal tissue from Hippocampus, purchased from Clontech. 
3.2 Other materials 
cDNA from liver and colon, and Marathon cDNA from cerebellum was purchased from Clontech. 
For detection of possible up- or downregulation of splice variants in cell lines cDNA from a Human 
Cell Line MTC™ panel (Clontech Cat# 636753) was used. U118 and N2A cell lines were 
purchased from ATCC (American Tissue Culture Collection). 
3.3 Methods 
3.3.1 RNA and DNA section
3.3.1.1 Total RNA isolation
This method was performed together with Anders Lorentzen. 
Total RNA was isolated from frozen U118 cell pellet (provided by A. Lorentzen), using SV Total 
RNA Isolation System (Promega). Cell pellet was thawed on ice and resuspended in Lysis buffer 
(RNA buffer, BMP). The cells were then transferred to a 2 ml QIAshredder column (Promega), and 
centrifuged 2 min at 14,500 RPM. 175 µl lysate was transferred to each of three eppendorf tubes 
and 350 µl RNA dilution buffer (Promega) was added. The samples were mixed well by pipetting. 
The tubes were placed at 70°C for 3 min, and centrifuged 10 min at 14,500 RPM. The cleared lysate 
was transferred to new tubes, 200 µl 96% Ethanol was added, and mixed by pipetting. The samples 
were applied to spin columns, centrifuged 1 min at 14,5000 RPM, and flow-through discarded. The 
columns were washed with 600 µl RNA wash buffer, centrifuged at 1 min at 14,500 RPM and the 
flow-though discarded. DNase incubation mix (Promega) was prepared; 40 µl yellow core buffer, 5 
µl 0.09 M MnCl2 and 5 µl DNase 1. 50 µl DNase mix was then added and samples incubated 15 
min. Hereafter 200 µl DNase stop solution was added and centrifuged 1 min at 14,500 RPM. 
Samples were washed twice, using RNA wash buffer (RWA); first time adding 600 µl RWA and 
spinning for 1 min at 14,500 RPM, and second time adding 250 µl RWA and spinning 2 min at 
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14,500 RPM. The column, containing the purified RNA, was put into a clean eppendorf tube, and 
100 µl DEPH-H2O was added. The samples were centrifuged for 1 min at 14,500 RPM to elute the 
RNA into the tube. RNA concentration was measured using an Eppendorf Biophotometer. 
Absorbance was measured at 260 nm, where the absorbance of 1 unit at 260 nm corresponds to a 
concentration of approximately 40 µg/ml.  
3.3.1.2 cDNA synthesis
This method was performed together with Anders Lorentzen. cDNA synthesis was performed using 
SuperScript III Reverse Transcriptase Kit (Invitrogen). 4.85 µl RNA and 6.15 µl H2O
(Approximately 1 µg RNA) was mixed with 1 µl 10 mM dNTPs, 1 µl T20 (Poly T sequence of 20 
T’s) primer (10 pmol/µl), 1 µl RH (Random Hexamer) primer (10 pmol/µl), 4 µl 5X First strand 
buffer, 1 µl 0.1M DTT and 1 µl Superscript reverse transcriptase, to a total of 20 µl. 
PCR program; 37°C for 30 min, 40°C for 5 min, 45°C for 5 min, 50°C for 60 min, 55°C for 15 min, 
60°C for 15 min, 65°C for 5 min, and hold on 4°C.
To control the cDNA synthesis, PCR was performed using glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as a positive control. The primers for amplifying GAPDH were designed 
by C. Mitchelmore; ‘GAPDH-for’ and ‘GAPDH-rev’. 17 µl H2O was mixed with 2.5 µl Buffer II 
(Advantage), 0.5 µl dNTPs (10 mM) and 0.5 µl Advantage II Polymerase. Then 2 µl GAPDH 
primer mix (5 pmol/µl of each) and 2.5 µl cDNA or H2O (negative control) was added to give a 
total of 25 µl, and the samples was gently mixed and spun down. PCR program; the thermo cycler 
was preheated 1 min at 94°C, and then the samples were loaded. 1 cycle at 94°C 1 min, 5 cycles at 
94°C 30 sec and 72°C 2 min, 20 cycles at 94°C 30 sec and 68°C 2 min, 1 cycle at 94°C 30 sec and 
68°C 5 min, and then 10°C at hold.
10 µl sample or control was mixed with 5 µl loading buffer, or 5 µl sample with 2.5 µl loading 
buffer, and loaded on a 1% agarose gel, to confirm the size of the PCR product (and thereby the 
presence of cDNA) in the cDNA+ sample and verify the absence of bands in the H2O sample .  
Designed primers were purchased from DNA Technology A/S. All primer sequences referred to in 
this section can be found in (Appendix II: Primers). 
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3.3.1.3 Comparative PCR
To investigate possible up- or downregulation of the chosen genes in CA1 tissue from AD 
patients/normal hippocampus tissue, various tissues (cerebellum, hippocampus, liver and colon), the 
cell line cDNA panel and U118 cell line a series of PCR’s were performed. Since the differences of 
some splice forms only spanned a few hundred basepairs, primers were designed to amplify short 
regions, so that the splice forms were easily distinguished from each other. Due to the different 
lengths of the amplification products and the primer compositions, different PCR programs were 
designed. Furthermore two different polymerases were used; an Advantage II polymerase 
(Clontech) and a Phusion Hot start polymerase (Finnzymes).  
The following PCR mixes were used with the polymerases; 
Advantage II polymerase: 17 µl H2O was mixed with 2.5 µl Buffer II (supplied with polymerase), 
0.5 µl dNTPs (10 mM) and 0.5 µl Advantage II Polymerase. Then 2 µl primer mix (5 pmol/µl of 
each) and 2.5 µl cDNA or H2O (negative control) was added to give a total of 25 µl, and the 
samples were gently mixed and spun down.  
Phusion hot start polymerase: 14.5 µl H2O was mixed with 5 µl GC Buffer (supplied with 
polymerase), 0.5 µl dNTPs (10 mM) and 0.5 µl Phusion hot start Polymerase. Then 2 µl primer mix 
(5 pmol/µl of each) and 2.5 µl cDNA or H2O (negative control) was added to give a total of 25 µl, 
and the samples were gently mixed and spun down.  
All samples were loaded on a 1% agarose gel, prepared by mixing 1 g agarose with 100 ml 1xTBE 
buffer, and boiling the mix in a microwave oven until the agarose was melted. The mixture was 
cooled a bit, and 10 µl (4 mg/ml) Ethidium Bromide (EtBr) was added. The mixture was then 
poured into a frame, spacers placed, and allowed to cool completely before removing the spacers. 
The gel was placed under tinfoil to avoid breakdown of EtBr by light.  
The gel electrophoresis was run in 1xTBE buffer with 0.4 µg/ml EtBr added. Samples were mixed 
with loading buffer, to help holding down the samples and to be able to see how far the DNA bands 
have migrated. The gel was photographed using an UV camera.  
Due to variations in cDNA amount in the examined tissues/cell lines and different primer 
combinations, different PCR programs were used in each examination. Each PCR was optimized 
through various tests for the specific splice variant and cDNA sample, and the final PCR conditions 
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are reported here. The following section is divided into the three experiments; PCR on AD/normal, 
tissues and cell lines.  
3.3.1.3.1 PCR on AD/normal tissue: 
PCR was performed on cDNA from AD CA1 tissue and normal hippocampal tissue, using the 
Advantage polymerase.  
Ephrin A3 amplification: A single primer set was constructed to amplify the two splice forms, 
giving two products of 196 bp and 261 bp; ‘Eph-for-3’ and ‘Eph-rev-2’. The PCR was run a Techne 
Thermocycler (Buch & Holm), using the PCR mix with the Advantage polymerase, and the 
following touch-down PCR program:  
The lid was preheated to 94 °C, then 1 cycle of denaturation at 94°C 2 min (samples were added 
after 1 min), 5 cycles at 94 °C 30 sec and 72 °C 2 min, 20 cycles at 94°C 30 sec and 68°C 2 min, 
and final elongation by 1 cycle at 68 °C 5 min. The samples were held at 10 °C until use.  
RGL1 amplification: Two sets of primers were designed to amplify the RGL1 splice forms.  
The RGL A splice form was examined by amplification by the entire ORF (2320 bp), using 
primers; ‘RGL-for-1’ and ‘RGL-rev-2’. The PCR was run on a Techne Thermocycler (Buch & 
Holm), using the PCR mix with the Advantage polymerase, and the following touch-down PCR 
program: The lid was preheated to 94 °C, then 1 cycle of denaturation at 94°C 2 min (samples were 
added after 1 min), 5 cycles at 94 °C 30 sec and 86°C 4 min, 25 cycles at 94°C 30 sec and 64°C 30 
sec and 68°C 4 min, and final elongation by 1 cycle at 68 °C 5 min. 8 µl of the PCR mix was 
removed from each sample and stored at -20°C. Hereafter an extra set of cycles was run, to get a 
higher product yield. The program was: The lid was preheated to 94 °C, then 1 cycle at 94°C 2 min 
(samples were added after 1 min), 5 cycles at 94 °C 30 sec and 86°C 4 min, and 1 cycle at 68 °C 5 
min. The samples were held at 10°C until use.  
The RGL C and M splice forms were examined with a single primer pair; ‘RGL-for-3’ and ‘RGL-
rev-4’ giving product sizes 306 bp and 416 bp. The PCR was run on a Biometra T-gradient 
thermocycler (Bie & Bernstein), using the PCR mix with the Advantage Polymerase. The program 
was: The lid was preheated to 94 °C, then 1 cycle of denaturation at 94°C 2 min (samples were 
added after 1 min), 47 cycles at 94 °C 30 sec and 70°C 2 min, and final elongation by 1 cycle at 70 
°C 5 min. 5 µl sample were then taken out, and 5 extra cycles were run to get a larger band of RGL 
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M in the AD sample: preheat at 94°C and then 94°C at 1 min, 5 cycles at 94°C 30 sec and 70°C 2 
min, and 1 cycle elongation at 70°C in 5 min. The samples were held at 10°C until loading on 
agarose gel. The RGL M band from the 47 + 5 cycles PCR was furthermore cut out from the 
agarose gel, and stored at -20°C.  
Ciz1 amplification: A single set of primers was also used for amplifying the three Ciz1 splice forms 
of sizes 584 bp, 500 bp and 417 bp; ‘Ciz-for-3’ and ‘Ciz-rev-4’. The PCR conditions for Ciz1 were 
the same as for Ephrin A3.  
Controls: To be able to compare the signal from PCR on AD cDNA and normal tissue cDNA, PCR 
was also performed for GAPDH. A region of 983 bp. was amplified, using primers; ‘GAPDH-for’ 
and ‘GAPDH-rev’. The PCR was run using the same PCR conditions as for Ephrin A3 and Ciz1.  
The mRNA level of GFAP, which as mentioned has previously been shown to be upregulated in 
Alzheimers tissue, and is therefore included as a positive control in this examination. The primers 
(‘GFAP-for’ and ‘GFAP-rev’) amplify a region of 424 bp. The PCR was run on a Techne 
Thermocycler (Buch & Holm), using the Advantage polymerase. The PCR program was: The lid 
was preheated to 94 °C, then 1 cycle of denaturation at 94°C 2 min (samples were added after 1 
min), 5 cycles at 94 °C 30 sec and 72 °C 2 min, 15 cycles at 94°C 30 sec and 68°C 2 min, and final 
elongation by 1 cycle at 68 °C 5 min. The samples were held at 10 °C until use.  
3.3.1.3.2 PCR on tissues 
PCR was run on cDNA from cerebellum, hippocampus, liver and colon. The number of cycles was 
adjusted to optimize the PCR, and Phusion hot start polymerase mix was used in all reactions.  
RGL1 amplification:
RGL A was examined by a new set of primers; ‘RGl-for-1’ and ‘RGL-rev-4’, giving a product size 
of 317 bp. The PCR was run on the Biometra T-gradient thermocycler, with the program: lid 
preheat to 95 °C, then 1 cycle of denaturation at 95°C 2 min (samples were added after 1 min), 34 
cycles at 94°C 30 sec and 65°C 2 min, and final elongation by 1 cycle at 64.4°C 5 min. The samples 
were held at 10 °C until use.  
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RGL C and M were examined by the same pair of primers as in AD/normal tissue PCR, on the T-
gradient thermocycler. The program was: lid preheating to 95 °C, then 1 cycle of denaturation at 
95°C 2 min (samples were added after 1 min), 28 cycles at 94°C 30 sec and 65°C 2 min, and final 
elongation by 1 cycle at 65°C 5 min. The samples were held at 10 °C, and hereafter another five 
cycles were run: lid preheating to 95 °C, then 1 cycle of denaturation at 95°C 2 min (samples were 
added after 1 min), 5 cycles at 94°C 30 sec and 65°C 2 min, final elongation by 1 cycle at 65°C 5 
min, and hold at 10°C.
Ciz1 amplification:
The same primers and thermocycler used for PCR on AD/normal tissue were also used here, but 
with the Phusion hot start polymerase. The program had a few more cycles: The lid was preheated 
to 94 °C, then 1 cycle of denaturation at 94°C 2 min (samples were added after 1 min), 5 cycles at 
94 °C 30 sec and 72 °C 2 min, 25 cycles at 94°C 30 sec and 68°C 2 min, and final elongation by 1 
cycle at 68°C 5 min. The samples were held at 10 °C until use.  
Control:
GAPDH was again used for normalizing the cDNA level in the examined tissues. The same 
primers, thermocycler, and PCR program was used here, as in the examination of AD/normal tissue.  
3.3.1.3.3 PCR on cell lines 
PCR was run on cDNA from cell lines; Ad5 (#293), Ovarian Carcinoma (#SKOV-3), 
Osteocarcinoma (#Saos2), Epidermoid carcinoma (#A431), prostatic carcinoma (#Du145), non-
small lung (#H1299), Hela (#CCL-2), MCF7(#HTB-22) and glioblastoma (U118). All splice forms 
were examined by amplification of smaller regions, and both polymerase mixes were used; the 
Phusion hot start polymerase mix was used for amplification of the RGL1 splice forms, and 
Advantage mix for the Ciz1 splice forms.  
RGL1 amplification:
Both RGL A mRNA and RGL C/M mRNA levels were examined like on the tissues. 
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Ciz1 amplification:
The same primers and thermocycler used for PCR on AD/normal tissue were also used here, but 
using the Advantage polymerase mix. The program was the same as when examining AD/normal 
tissue; The lid was preheated to 94 °C, then 1 cycle of denaturation at 94°C 2 min (samples were 
added after 1 min), 5 cycles at 94 °C 30 sec and 72 °C 2 min, 20 cycles at 94°C 30 sec and 68°C 2 
min, and final elongation by 1 cycle at 68 °C 5 min. The samples were held at 10 °C until use.  
Control:
GAPDH was again used for normalizing the cDNA level from the cell lines. The same primers, 
thermocycler and PCR program was used here, as were in AD/normal tissue PCR’s, but PCR was 
performed with both polymerase mixes.  
3.3.1.4 PCR cloning
The entire ORF of RGL C was amplified by PCR on cDNA from normal hippocampus tissue, and 
Ciz F, M and RGL A splice forms were amplified using cDNA from cerebellum. However, it was 
not possible to amplify the Ciz L splice variant, within the set time range, so only the Ciz F and M 
variants were cloned for further investigation. All PCR products were loaded on a 1% agarose gel 
with EtBr, excised with a scalpel, and gel purified.  
RGL1 ORF amplification:
The ORF of RGL A was amplified using primers; ‘RGL-for-1’ and ‘RGL-rev-2’ and the RGL C 
ORF using; ‘RGL-for-3’ and ‘RGL-rev-2’. Both PCRs were run using the Advantage polymerase 
mix, the Techne Thermocycler and the PCR program: The lid was preheated to 94 °C, then 1 cycle 
of denaturation at 94°C 2 min (samples were added after 1 min), 5 cycles at 94 °C 30 sec and 68 °C 
4 min, 25 cycles at 94°C 30 sec, 64°C 30 sec and 68°C 4 min, and final elongation by 1 cycle at 68 
°C 5 min. Hold at 10 °C.   
Ciz1 ORF amplification:
Both entire ORFs of the Ciz1 splice forms were amplified using primers; ‘Ciz-for1’ and ‘Ciz-rev-
2’, the Advantage polymerase mix and the Techne Thermocycler. The PCR program was: The lid 
was preheated to 94 °C, then 1 cycle of denaturation at 94°C 2 min (samples were added after 1 
min), 5 cycles at 94 °C 30 sec and 72 °C 4 min, 25 cycles at 94°C 30 sec and 68°C 4 min, and final 
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elongation by 1 cycle at 68 °C 5 min. Hold at 10 °C. The two splice variants were separated on a 
long 1% agarose gel, and excised carefully with a scalpel.  
3.3.1.5 5’RACE
5’ RACE was performed using marathon ready Hippocampus cDNA (Clontech Cat# 639319). 
Marathon ready cDNA is made from PolyA+ RNA, where the first strand synthesis is performed by 
using a primer that attaches to the poly A tail. Second strand synthesis is performed, with a T4 DNA 
polymerase creating blunt ends. An adaptor is ligated to both ends of the cDNA, and thereby 
creating a known sequence upstream all the cDNA sequences. A supplied primer binding to this 
adaptor, together with a User-defined primer can then be used for amplifying the 5’ or 3’ end of the 
wanted gene.  
First 5’ RACE was performed using the supplied Adaptor primer 1 (AP1) and an RGL-specific 
primer; ‘RGL-rev-4’. 1 µl AP1 (10 pmol/µl) was mixed with 1 µl RGL-rev-4 primer (10 pmol/µl), 
5 µl 10X advantage buffer, 1 µl 10mM dNTPs, 36 µl H2O and 1 µl Advantage Polymerase, to a 
total of 50 µl. Hot start PCR was run on the Biometra thermocycler, using touch down PCR in the 
program to improve the specificity; 1 min at 94°C; 5 cycles at 94°C 30 sec, 72°C 3 min; 5 cycles at 
94°C 30 sec, 70°C 3 min; 30 cycles at 94°C 30 sec, 68°C 3 min; 1 cycle at 68°C 10 min. The 
samples were mistakenly run another 5 cycles at the program: 1 min preheat at 94°C, 5 cycles at 
94°C 30 sec and 68°C 3 min, and hold at 10°C.  
The reaction was column purified, and nested RACE was performed using the supplied, nested 
Adaptor primer 2 (AP2) and a nested RGL-specific primer; ‘RGL-nested’. 1 µl purified First 
5’RACE reaction was mixed with 1 µl AP2 (10 pmol/µl), 1 µl RGL-nested primer (10 pmol/µl), 40 
µl H2O, 5 µl 10X Advantage buffer, 1 µl dNTPs and 1 µl Advantage polymerase, to a total of 50 µl. 
Hot start and touch down PCR was also used here; 1 min at 94°C; 5 cycles 94°C 30 sec, 72°C 2 
min; 20 cycles at 94°C 30 sec, 70°C 2 min; 1 cycle at 68°C 10 min.  
3.3.1.6 Gel-purification of DNA fragments
PCR fragments were purified using the High Pure PCR product purification kit (Roche) 
PCR reactions were loaded onto a 1% agarose gel, the bands cut out with a scalpel, and placed in a 
sterile eppendorf tube. (Sometimes the tubes were stored at -20°C until use). The gel slice was 
weighed and 300 µl binding buffer was added for every 100 mg agarose to each tube. The samples 
placed in a heating block at 56°C, mixed a few times, and removed when the gel was melted. 150 µl 
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Isopropanol was then added to each tube, for every 100 mg agarose, and the samples mixed. The 
samples were then applied into a High Pure filter column, which binds the DNA, centrifuged 60 sec 
at 13,500 RPM and the flow through discarded. If the volume of the samples exceeded the capacity 
of the filter, the rest was applied to the same column, and the samples centrifuged again. 500 µl 
wash buffer was then added to each filter, the samples spun for 1 min at 13,500 RPM and the flow 
through discarded. The wash was repeated with 200 µl wash buffer, centrifugation at 13,500 RPM 
for 1 min and flow through discarded. The purified DNA was eluated into an eppendorf tube, by 
addition of 50 µl elution buffer and centrifugation at 13,500 RPM for 1 min. The samples were 
stored at 4°C. 
3.3.1.7 Column purification 
5’RACE products were purified using the High Pure columns (Roche). 5 volumes binding buffer 
was added to 40 µl 5‘RACE product, the sample mixed and applied to a High Pure column filter. 
The sample was spun down 30 sec at 13,000 RPM, the flow through discarded and 0.5 ml wash 
buffer applied. The sample was then centrifuged again at 13,000 RPM for 30 sec, and the flow 
through discarded. The wash was repeated with 0.2 ml wash buffer, and centrifugation at 13,000 
RPM for 30 sec. The purified DNA was then eluated into a clean eppendorf tube, with 50 µl H2O.
The sample was stored at -20°C.  
3.3.1.8 Topo TA cloning
The PCR amplified products were cloned into pCR®4-TOPO® vectors (Fig. 3-1) using the TOPO 
TA Cloning kit (Invitrogen). The Topo TA cloning method utilizes that Taq polymerases creates A-
overhangs at both the 5’ and 3’ end of the cDNA. The pCR®4-TOPO® vector is linearized, with T-
overhangs at each end and has a topoisomerase bound to both ends. When the PCR product with T 
overhangs is mixed with the TOPO vector, the overhangs are joined and the topoisomerase released.  
2 µl ds cDNA with TA-overhangs was mixed with 0.5 µl salt solution and 0.5 µl TOPO vector, both 
supplied in the kit. The samples incubated 15-30 min at room temperature, and were then placed on 
ice until transformation.  
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3.3.1.9 Expression vectors
The pcDNA™6/V5-His A vector (Fig. 3-2) was used for expression of the various splice forms. 
The XhoI and XbaI site was used for insertion in the vector. The inserts were hereby placed under 
regulation of the CMV promoter, and placed in-frame with the V5-epitope, to create proteins with 
this epitope in the C-terminal end. The constitutive promoter CMV secures a high expression of the 
various constructs in mammalian cells.  
Fig. 3-1. Illustration of the pCR®4-TOPO® vector (Invitrogen) 
Fig. 3-2. pcDNA™6/V5-His A vector.  
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3.3.1.10 Transformation of E.coli
All TOPO TA clones were transformed into High Efficiency GC10 Competent cells (GeneChoice), 
and all pcDNA™6/V5-His A vectors (Invitrogen) into XL10 Gold cells (Stratagene). The purpose 
of using competent cells is to ensure efficient uptake of DNA and no degradation of it, due to 
bacterial restriction-modification systems.  
For each transformation one vial of competent cells was thawed on ice, and gently mixed. All the 
cloning reaction was added to the tube, and mixed gently. The samples incubated 30-60 min on ice, 
were heat shocked for 45 sec at 42°C, and then immediately transferred to ice.  450 µl S.O.C. 
medium (Invitrogen) was then added to each tube, and the lids closed tightly. The samples were 
then placed in a 37°C waterbath for 30-60 min. The cells were then spread on pre-dried LB+AMP 
plates, divided in 100 µl and the rest of the cells. The plates were incubated upside-down at 37°C 
overnight (approx. 16 hours).  
3.3.1.11 Digestion of plasmid DNA and PCR products
Cloned TOPO vectors were controlled by digestion, before sequencing them.  
RGL A, C and partial M TOPO vectors were cut with EcoRI, and Ciz F and M with Not1 to control 
correct insertions. 3 µl plasmid DNA was mixed with 1 µl restriction enzyme, 2 µl (10X) buffer 
(NE4 for NcoI, NE3 for NotI, and EcoRI buffer for EcoRI), and 14 µl H2O, giving a total volume of 
20 µl. Samples were placed at 37°C for 1-2 hours.  
Cloned TOPO vectors and pcDNA™6/V5-His A vectors were digested with XhoI and XbaI using 
10 µl plasmid, 1 µl XhoI, 1 µl XbaI, 3 µl NE 2 buffer, 3 µl BSA (10 1 mg/µl) and 12 µl H2O, to a 
total volume of 30 µl. The samples were placed in 37°C for 1-2 hours. 
The pcDNA™6/V5-His A vector with RGL C inserted and RGL M PCR product was digested with 
XhoI and HindIII, to create an expression vector with the RGL M splice form. 10 µl plasmid was 
mixed with 1 µl XhoI, 1 µl HindIII, 3 µl NE buffer 2, 15 µl H2O, to a total volume of 30 µl. The 
samples were placed in 37°C for 1-2 hours. 
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All digestions were controlled by loading 1 µl sample and 1 µl loading buffer (mixed) before 
ligations, and 10 µl sample and 5 µl loading buffer for controls, onto a 1% agarose gel with EtBr 
and photographing it using an UV camera.  
3.3.1.12 Ligation
Gel purified digested inserts and pcDNA™6/V5-His A vectors were ligated using T4 DNA ligase 
(Biolabs). 2 µl vector and 8 µl insert was mixed to be sure to have an abundance of insert. Then 10 
µl Quick ligase buffer (supplied with kit) and 1 µl T4 ligase was added, to a total of 21 µl. The 
samples were gently mixed and incubated 5 min at room temperature.  
3.3.1.13 Sequencing
All cDNA clones were sequenced using the ABI-Prism® BigDye™ Terminator Cycle Sequencing 
kit (PE Applied Biosystems). The method is based on thermo cycling with an AmpliTaq®DNA 
polymerase, and utilizes the incorporation of dye labeled ddNTPs. Each of the four ddNTPs has a 
unique fluorescence color. Since incorporation of ddNTPs results in termination of the DNA 
replication, all copies of the DNA strand will have a dyed ddNTP in the end. The polymerase will 
incorporate ddNTPs at random places, and thereby produce DNA fragments of varying lengths. The 
sequence reaction is loaded in a laser sequencer, which separates the fragments by high voltage 
capillary electrophoresis, and reads the data.  
4 µl Terminator “Ready Reaction” mix was mixed with 1µl sequencing primer (1.6 pmol/µl), 3 µl 
plasmid DNA and 2 µl H2O. Samples were mixed, spun down and transferred to a Techne 
Thermocycler. The program was: 25 cycles at 96°C 30 sec and 50°C 15 sec and 60°C 4 min. 
Samples were held at 4°C until use.  
The sequence reactions were purified by adding 40 µl 75/25% isopropanol/H2O, mixed and left on 
the bench for 15 min. Samples were spun down at 14,500 RPM for 30 min at 4°C, and the liquid 
immediately discarded. 125 µl 75/25% isopropanol/H2O was then added, mixed and spun down at 
14,500 RPM for 15 min at 4°C. The liquid was discarded and the pellet dried in a heating block for 
2-5 min at 90°C.
15 µl formamide was added to each sample, the tubes mixed and spun down. Samples were 
transferred to sequencing tubes and stored at -20°C until loading. Samples were loaded in an ABI 
Prism 310 Genetic Analyzer, by a technician.   
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3.3.1.14 Micro-scale preparations of plasmid DNA (Mini preps)
Glycerol cultures were streaked on LB with ampicillin (AMP) (100µg/ml) plates, and grown in 
37°C overnight. A single coloni was then inoculated in 3 ml LB with AMP (100µg/ml), and grown 
in a shaking incubator at 37°C overnight. 2 ml bacterial culture was pelleted at 13,500 RPM for 5 
min, and plasmid DNA purified using High Pure plasmid purification kit (Roche). 
The pellet was resuspended in 250 µl suspension buffer and mixed well. 250 µl lysis buffer was 
then added, gently mixed and left on the bench for 5 min, to allow the cells to lyse. 350 µl binding 
buffer was then added, the samples inverted 4-5 times, and put on ice for 5 min. The tubes were 
then centrifuged 10 min at 13,500 RPM, the supernatant transferred to a High Pure filter column 
and centrifuged again at 13,000 RPM for 60 sec. The flow through was discarded, 500 µl wash 
buffer I applied to the column and the samples centrifuged at 13,000 RPM for 60 sec. The flow 
through was discarded and the wash repeated with 700 µl wash buffer II, and centrifugation at 
13,000 RPM for 60 sec. The flow through was discarded and the samples centrifuged 60 sec at 
13,000 RPM to remove any residual wash buffer. The filter was then applied to a clean collection 
tube, 50 µl elution buffer added, and the purified plasmid DNA eluted by centrifugation 30 sec at 
13,000 RPM. The mini preps were stored at 4°C.  
3.3.1.15 Glycerol cultures
Glycerol cultures were prepared from all transformations. 250 µl 78% Glycerol was added to 750 µl 
bacterial culture, to stabilize the cells when frozen, and then mixed. The glycerol cultures were 
stored at -80°C.  
3.3.1.16 Large-scale preparations of plasmid DNA (Midi preps)
Glycerol cultures were streaked on LB+AMP (100µg/ml) plates, and grown in 37°C overnight. One 
colony was inoculated in 5 ml LB+AMP (100µg/ml), and incubated shaking at 37°C for approx. 8 
hours. 100 µl starter culture was then added to a 250 ml Erlenmeyer flask with 50 ml LB+AMP, 
and grown in a shaking waterbath at 37°C overnight. Plasmid DNA was then purified using 
QIAfilter Midi Kit (Qiagen).  
40 ml culture was centrifuged at 6,000 G for 15 min, to pellet the cells. The pellets were 
resuspended in 7 ml Buffer P1 (kit), 7 ml Buffer P2 added, and the tubes inverted 4-6 times. The 
samples incubated 5 min at room temperature, to allow the cells to lyse. Then 7 ml Buffer P3 was 
added, the tubes inverted 4-6 times, and the lysate poured into a QIAfilter cartridge. After 10 min 
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incubation at room temperature, a layer of proteins, genomic DNA and detergent floated on top, and 
the lysate containing the plasmid DNA could be pressed out through the filter outlet nozzle. The 
lysate containing the plasmids was applied to a QIAGEN-tip, which had been equilibrated with 10 
ml QBT buffer. After the lysate had passed through the tip, 10 ml QC (wash) buffer was applied, 
the tip allowed to drain, and another 10 ml QC buffer applied. The plasmid DNA was then eluted 
into clean tubes, by addition of 10 ml Buffer QF.  
7 ml Isopropanol was then added to each tube, the samples mixed and then centrifuged immediately 
at 15,000 G for 30 min at 4°C. The supernatant was carefully removed, and the DNA pellet washed 
with 2 ml 80% Ethanol, and centrifuged at 15,000 G for 10 min at 4°C. The supernatant was then 
removed and the pellet air-dried for 5-10 min. The plasmid DNA was then resuspended in 500 µl 
TE-buffer (10 mM Tris (pH 7.5) and 1 mM EDTA (pH 8.0)), and stored 4°C.  
3.3.1.17 Site directed Mutagenesis
Sitedirected mutagenese was carried out, using QuikChange II (Stratagene). The method is based on 
linear amplification with mutagenic primers, resulting in a parental strand with the original 
sequence and a new strand with a mutated sequence. Hereafter the fact that newly synthesized DNA 
is un-methylated, and the parental DNA strand is methylated on all adenines, is utilized. The 
restriction enzyme DpnI has the target sequence “5’ Gm6ATC 3’”, and will therefore cut nicks in the 
parental strand, and not in the new strand. The parental strand can hereafter be digested with a 
restriction enzyme, and the mutated new strand transformed into E coli cells.   
Two complementary primers containing a single mutation in the middle were designed; ‘ciz-mut-
for’ and ‘ciz-mut-rev’. Linear amplification was performed (1x 95°C for 30 sec; 16x 95°C for 30 
sec, 55°C for 60 sec, 68°C for 60 sec), and hereafter the parental strand was digested for 1 hour at 
37°C, using 10 U/µl DpnI.  
3.3.2 Cell section
3.3.2.1 Cell culture and Transfection
Mouse neuroblastoma (N2A) cells were grown in cell medium (450 ml Dulbecco’s modified Eagles 
medium (DMEM) (Invitrogen) was mixed with 5 ml Pen/Strep (Invitrogen) and 50 ml Fetal Bovine 
Serum (FBS) (Invitrogen)) at 37°C and 5% CO2.
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Day 1: Cells were counted using a hemocytometer. 2.5 x 105 cells were plated in 6 wells plates with 
3 ml cell medium, and grown for 24 hours.  
Day 2: 200 µl Optimem was added to 50 µl (4 µg) plasmid DNA. For each tube 245 µl Opti-Mem 
medium (Invitrogen) was mixed with 5 µl Lipofectamine 2000 (Invitrogen), and incubated for 5 
min at room temperature. The 250 µl Lipofectamine mix was then added to the DNA mix, and 
incubated 20 min at room temperature. The cell medium was changed on the cells in the meantime. 
Finally the 500 µl mixture was added to each well, and mixed gently. The cells were then grown for 
48 hours. 
Day 4: Cells were washed with 3 ml phosphate buffered saline (PBS), and then harvested by adding 
500 µl trypsin, incubation for 5 min at 37°C, resuspension in 1 ml medium and centrifugation at 
5,000 RPM for 2 min. Cell pellets were placed on ice, or stored at -20°C until use.  
3.3.2.2 Immunostaining
All washes were done in a 24 well plate on a rocker at room temperature. 
Day 1: Coverslips were placed in a 24 well plate, and sterilized with 85% Ethanol. 1 ml medium 
was then added to each well, and 2x104 cells seeded. Cells were grown for 24 hours.  
Day 2: 40 µl Opti-Mem was added to 10 µl (0.8 µg) plasmid DNA. 1 µl Lipofectamine 2000 was 
then mixed with 49 µl Opti-Mem, and incubated for 5 min at room temperature. The Lipofectamine 
mix was then added to the DNA mix, and incubated for 20 min at room temperature. The cell 
medium was then changed, the plasmid mix added to each well and mixed, and the cells were then 
allowed to grow for 48 hours.  
Day 4: The coverslips were washed with 500 µl cold PBS, fixed 5 min in 500 µl cold Methanol and 
washed twice in 500 µl PBS. The coverslips were hereafter blocked using 1X PBS with 0.2% 
Triton-X 100 (Sigma) and 3% BSA, for 20 min at 37°C.  The coverslips were placed on parafilm 
and incubated in a humidity chamber overnight at 4°C, with 25 µl primary antibody solution (1X 
PBS with 0.2% Triton-X 100, 3% BSA and primary antibodies (mouse anti-V5 (diluted 1:400), 
rabbit anti-V5 (diluted 1:800), mouse anti--Tubulin (diluted 1:200)) (see 3.3.3.7 for source and 
fluorophore of antibodies). 
The coverslips were then placed in a clean 24 well plate, and washed three times with 1X PBS with 
0.2% Triton-X 100, for 15 min in total. Hereafter the coverslips were placed on parafilm in a 
humidity chamber covered with tin foil, and incubated with 25 µl secondary antibody solution (1X 
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PBS with 0.2% Triton-X 100, 3% BSA, and secondary antibodies; anti rabbit (1:400) and anti-
mouse(1:1,000)) for 30 min at 37°C.  
The coverslips were again washed three times with 1X PBS with 0.2% Triton-X 100, for 15 min in 
total, and mounted on microscope slides using Vectashield mounting medium with DAPI (Vector). 
Images of fluorescence were taken using a Leica FW 4000 camera with a 100X oil objective. 
Images were manipulated using Leica FW 4000 software and Image J (freeware) to adjust colors 
and contrast, merge pictures and insert scalebar.  
3.3.3 Protein section
3.3.3.1 The V5 epitope
Instead of using antibodies raised directly against Ciz1 or RGL1, and thereby using time on 
optimization of these, it was chosen to use an epitope tag to identify the proteins in western blots 
and immunofluorescence stainings. Therefore all expressed proteins are designed to have a V5 
epitope as well as a 6x Histidine tag attached to the C-terminal end (Fig. 3-3), in phase with the 
ORF. The V5 epitope consists of only 14 amino acids; ‘GKPIPNPLLGLDST’, which compared to 
larger epitopes like e.g. Green Fluorescence Protein (GFP) of 238 aa, is less probable to interfere 
with the folding of the protein, and thereby its function.  
Fig. 3-3. The Ciz1 and RGL1 proteins have a V5-epitope attached to the C terminal end.  
3.3.3.2 In vitro transcription/translation
To test the various constructs for correct protein size and functional V5 epitope, an in vitro
transcription/translation was carried out using the TNT® T7 quick coupled 
Transcription/Translation (Promega). The proteins get radioactive labeled methionine incorporated 
during translation of the various transcripts, and can thereby be visualized in a phosphor-imaging 
cassette.   
10 µl TNT T7 Master Mix (kit), 0,5 µl [S35]-Methionine (1000 Ci/mmol at 10 mCi/ml) and approx. 
200 ng plasmid were mixed and incubated 90 min at 30°C. The samples were put on ice, and 2 µl 
sample was then mixed with 2 µl H2O, 8 µl 2X Tris-Glycine SDS (sodium dodecyl sulphate) 
loading buffer, and 3 µl 0.5M DTT. The samples were heated for 10 min at 70°C, spun down and 
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immediately loaded on a SDS-polyacrylamid gel, next to 10 µl SeeBlue Plus2 prestained protein 
molecular weight marker (Invitrogen). Hereafter the gel was placed on a piece of Whatman paper, 
cling film was used for covering the gel, and then it was dried. The gel was then placed in a 
phosphor-imaging cassette to visualize the protein bands.   
3.3.3.3 Whole cell protein extraction
The protocol is adapted from (Sawamura et al., 2005).
Cell pellet was washed twice in 1 ml PBS right after harvesting, and the pellet frozen. Frozen cell 
pellet was resuspended in 50 µl lysis buffer (20 mM Hepes (pH=7.9), 1.5 mM MgCl2, 420 M NaCl, 
25% Glycerol, 1 mM DTT, protease inhibitor (Sigma) (1:500)) (DTT and protease inhibitor was 
added right before use). Samples incubated 30 min on ice, and were centrifuged 10 min at 14,000 g 
at 4°C. Supernatant was transferred to new tubes and labeled “whole cell extract”.  
3.3.3.4 Cell fractionation
This protocol is adapted from (He et al., 1990;Farley et al., 2006), which fractionates cells in the 
following fractions; “Soluble” (containing soluble proteins from cytosol and nucleus), “Chromatin 
DNase” (containing proteins bound to DNA, which is released by DNase digestion of chromatin), 
“Chromatin NaCl” (containing proteins bound to the rest of the chromatin, which is released by 
high salt concentration) and “Nuclear Matrix” (containing proteins bound to the filamentous 
network referred to as the ‘nuclear matrix’).  
Cell pellets were resuspended in PBS, centrifuged 5 min at 2000 RPM, and the PBS was removed. 
This step was repeated once. The cell pellet was resuspended in cold cytoskeletal (CSK) buffer (20 
mM PIPES (Sigma), 100 mM NaCl, 300 mM Sucrose, 3 mM MgCl2, 1 mM EGTA (Sigma), 
protease inhibitor (1:500) (Sigma), 0,5% Triton X, pH adjusted to 7.0), incubated at room 
temperature for 5 min and centrifuged 5 min at 2000 RPM. The supernatant was collected and 
labeled “Soluble fraction I”. This step was repeated once, and this supernatant was labeled “soluble 
fraction II”. The pellet was resuspended in CSK buffer with 250 units/ml added DNase I (Roche), 
incubated 15 min. at room temperature, and followed by 20 min at 37°C. Then (NH4)2SO4 was 
added to give a final concentration of 0.25 M, and the samples were incubated 5 min on ice. 
Hereafter the samples were centrifuged at 8000 RPM for 5 min. The supernatant was collected and 
labeled “Chromatin DNase fraction”. The pellet was then resuspended in 2 M NaCl CSK buffer, 
incubated 5 min on ice, and centrifuged 5 min. at 13,000 RPM. The supernatant was collected and 
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labeled “Chromatin NaCl fraction”. The remaining pellet was resuspended in 8M UREA solution 
(8M UREA (pH 8.0), 100 mM NaH2PO4, 10 mM Tris-HCl), and labeled “Nuclear Matrix fraction”. 
All protein fractions were stored at -20°C. 
3.3.3.5 SDS-PAGE
Protein concentrations were measured using a standard Bradford assay. Standard curves were 
created with known protein concentrations of bovine serum albumin (BSA), using a BioPhotometer 
(Eppendorf). Samples were examined by SDS-PAGE (poly acrylamide electrophoresis) loaded on 
4-12% SDS gels (Anamed, Kem-En-Tec) as well as a SeeBlue Plus2 prestained standard protein 
ladder (Invitrogen). 
8 µl protein extract was mixed with 10 µl 2X Tris-Glycine SDS loading buffer and 2 µl 0.5M DTT. 
Samples were heated 10 min at 70°C before loading.  
3.3.3.6 Western blotting
The SDS gel was electroblotted to a PVDF transfer membrane (Amersham), and blocked using 
ECL membrane blocking agent (GE healthcare). All washes/incubations were done on a rocker at 
room temperature. 
The membrane was incubated in 20 ml blocking buffer (1X PBS with 0.1% Tween-20 (Sigma) and 
1 g blocking agent) for 30 min. The membrane was washed twice in 20 ml wash buffer (1X PBS 
with 0.1% Tween-20), and then incubated 1-1½ hour in 10 ml dilution buffer (1X PBS with 0.1% 
Tween-20 and 0.25 g blocking agent) with a 1:20.000 dilution of primary antibody (2 µl prediluted 
(1:4) mouse V5-antibody). 
The membrane was then washed 2 x 10 min with 20 ml wash buffer, and then incubated 1 hour in 
10 ml dilution buffer with a 1:10.000 dilution of secondary antibody (1 µl goat anti-mouse 
antibody).  
The membrane was hereafter washed 4 x 10 min in 20 ml wash buffer, and placed on a plastic wrap.  
The membrane was then treated with detection reagent, by mixing 1.5 ml of each reagent from the 
Supersignal West DURA extended duration substrate kit (Pierce), and pipetting the mix onto the 
membrane. After 5 min incubation, the blot was placed in plastic wrap and images recorded using 
Biospectrum AC Imaging System (UVP). Hereafter the membrane was washed 5 min in distilled 
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water, stripped in 0.2 M NaOH for 5 min, and washed 3 x 2 min in distilled water again. The 
membrane was stored at 4°C in H2O overnight.  
Blots of whole cell extracts were then incubated with -Actin antibody to control loading amounts, 
using the same procedure as described above. Primary antibodies were however incubated 
overnight at 4°C. Mouse -Actin antibody was diluted 1:5000 (2 µl in 10 ml dilution buffer), and 
goat anti-mouse antibody was diluted 1:10,000 (1 µl in 10 ml dilution buffer).  
Blots of cell fractionation were incubated with three antibodies at the same time (against -Tubulin,
Histone H3 and Lamin A/C) for controlling loading and the purity of the fractions. The same 
procedure was used as first described. All three primary antibodies were diluted in 20 ml dilution 
buffer (2 µl anti--Tubulin (1:10,000), 2 µl anti-Histone (1:10,000), and 5 µl anti Lamin (1:4000)), 
and also both secondary antibodies was mixed together in 10 ml dilution buffer with 1 µl anti-
mouse (1:10,000) and 2 µl anti-rabbit (1:5000).  
3.3.3.7 Antibodies
Primary antibodies: 
Monoclonal mouse V5-antibody (Invitrogen Cat# R960-25) and Rabbit V5-antibody (Sigma 
product# V8137) specifically recognizes the 14 amino acid long V5 epitope (sequence; 
GLPIPNPLLGLDST). V5-antibody raised in mouse was used in all western blots, and the first 
immune staining. In the second immune staining the cells were co-stained with mouse -Tubulin
antibody, and rabbit V5-antibody was therefore used here.  
Monoclonal mouse -Tubulin antibody (Sigma product# T 6199) targets an epitope at the C-
terminal end of -Tubulin (aa 426-430). Tubulin, which is found in microtubules e.g. in the 
cytoskeleton, is made up by a heterodimer with - and -Tubulin, and both subunits have a 
molecular weight of approx. 50 kDa.  
Monoclonal mouse -Actin antibody (Sigma product# A 5441) targets an N-terminal epitope of -
Actin. The protein weighs 43 kDa and is a key cytoskeletal protein involved in many cellular 
processes, e.g. locomotion.  
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Histone H3 antibody was raised in rabbit (Sigma product# H 0164) and recognizes amino acids 
125-136 in the C-terminal end of Histone H3. Histone H3 is a 17 kDa protein which, together with 
four other histones, has a function in folding DNA into the dense chromatin structure.  
Anti-Lamin A was developed in rabbit (Sigma Cat# L 1293) and targets the C-terminal end of both 
the Lamin A and C isoform, which therefore gives two bands of approx. 70 kDa, in western blots. 
Lamin is a major component of the nuclear lamina, on the inner side of the nuclear membrane.  
Secondary antibodies: 
Stabilized Goat anti-Mouse antibody HRP (Pierce product# 1858413) and stabilized Goat anti-
Rabbit antibody HRP (Pierce product# 1858415) were used as secondary antibodies in all western 
blots.
Secondary antibodies (Fluorescence): 
Alexa Fluor® 568 goat anti-rabbit antibody (Invitrogen Cat# A11036) which emits red light when 
excited in a fluorescence microscope, and Alexa Fluor® 488 goat anti-mouse antibody (Invitrogen 
Cat# A11029) which emits green light, were used for immunofluorescence staining of cells. 
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4 Results
4.1 Expression analysis of Alzheimer’s Disease Tissue and Normal Hippocampus Tissue 
Possible upregulation in mRNA levels of EphrinA3, RGL1 and Ciz1 in AD tissue was investigated 
by PCR on first strand cDNA pooled from the CA1 region of four AD patients and from non AD 
hippocampal tissue (Fig. 4-1). The presented results are a representative of two-three repetitions of 
the experiments.  
GAPDH was used for normalization of the amount of template. Normal tissue has slightly more 
signal, and this should be taken into account when comparing the other results. As a positive 
control, GFAP was furthermore included.  
The relatively large size of the RGL1 and Ciz1 PCR product made it difficult to compare the 
results, and therefore primers were designed to amplify short regions of the products.  
Fig. 4-1. PCR products with cDNA from AD-CA1 tissue and 
normal hippocampus tissue. 
PCR was run using the following primer sets, with expected 
sizes; Eph (Eph-for-3 + Eph-rev-4; 261/196 bp), Ciz F/M/L 
(Ciz-for-3 + Ciz-rev-4; 584/500/417 bp), RGL A (RGL-for-1 
+ RGL-rev-2; 2320 bp), RGL C/M (RGL-for-3 + RGL-rev-4; 
416/306 bp), GAPDH (GAPDH-for + GAPDH-rev; 983 bp) 
and GFAP (GFAP-for + GFAP-rev; 424 bp). 5 µl sample was 
run on a 1% agarose gel + EtBr, and UV photographed.  
GAPDH is used for normalization of template amounts, 
though the signal in normal tissue is slightly stronger. GFAP 
is shown as a positive control, which has a higher expression 
in AD. 
These results seem to indicate that Ciz L is slightly 
upregulated in AD tissue. RGL C seem completely absent or 
much downregulated in AD tissue, and a new splicevariant; 
RGL M, seems slightly downregulated in AD tissue. 
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Compared to the GAPDH expression, EphrinA3 does not appear to be upregulated in AD tissue, but 
the smaller splice form (Eph L) seems slightly downregulated compared to Eph F. 
For Ciz1 the same results appear; No upregulation is seen with the full length splice form (Ciz F), 
and the smaller splice form (Ciz L) is less expressed than Ciz F. Though, the smaller splice form 
(Ciz L) appears upregulated in AD tissue. The Ciz M variant appears completely absent in both AD 
and normal tissue (see Appendix IV: PCR on Ciz1). RGL A does not seem to have a higher mRNA 
expression in AD tissue. RGL C, though appears completely missing or heavily downregulated in 
AD tissue, since no product was seen after 47 cycles. The newly identified splice form RGL M also 
appears downregulated in AD tissue.  
These results seem to indicate that the smaller, alternatively spliced variants of both RGL1 and Ciz1 
transcripts have an altered expression. But where the shorter variants of RGL1 appear 
downregulated, the small Ciz1 variant seems upregulated. On the basis of these results it was 
decided not to proceed with the investigation of Ephrin A3, since it did not appear to have an 
altered expression in AD tissue and the role of the Ephrin A3 gene product is relatively known. 
Instead the remaining experiments will focus on Ciz1 and RGL1 since they both are relatively 
unknown genes, with interesting proposed functions for their gene products. 
4.2 Expression analysis in different Tissues 
An mRNA expression analysis was carried out on cDNA from selected tissues, to examine the 
expression pattern of the different RGL1 and Ciz1 splice forms (Fig. 4-2). PCR was performed on 
double-stranded Marathon ready cDNA from hippocampus and cerebellum, as well as first-strand 
cDNA from liver and colon. All presented results were reproduced two to three times, and a 
representative result shown. GAPDH is used again for normalization of the cDNA level, though the 
template level in hippocampus was slightly lower than the rest.  
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Fig. 4-2. Hot start PCR on cDNA from 
hippocampus, cerebellum, liver and colon.  
PCR was run using the following primer sets, 
with expected sizes; CizF/M/L (Ciz-for-3 + Ciz-
rev-4; 584/500/417 bp), RGL A (RGL-for-1 + 
RGL-rev-4; 317 bp), RGL C/M (RGL-for-3 + 
RGL-rev-4; 416/306 bp), GAPDH (GAPDH-for 
+ GAPDH-rev; 983 bp). 10 µl sample was 
mixed with 5 µl loading buffer and run on a 
1% agarose gel. The gel was then 
photographed in an UV chamber. 
GAPDH was used for normalizing the cDNA 
levels, though the signal in Hippocampus is 
slightly lower than the rest. All Ciz1 and RGL1 
splice forms appears to have a higher 
expression in brain tissue, than the other 
examined tissues; liver and colon, and again 
the Ciz M variant appears to have a very low 
expression.
Ciz F seems to have a bit lower expression in liver, and the same pattern is seen with Ciz L, though 
the general expression of Ciz L is much lower than Ciz F. The Ciz M variant again appears to have 
a very low expression. All RGL1 splice variants seem to have a lower expression in liver and colon, 
compared to the brain tissues; cerebellum and hippocampus. It is however important to have in 
mind that the used cDNA samples are not completely comparable since the hippocampus and 
cerebellum cDNA is double stranded and the liver and colon cDNA is single stranded. Therefore a 
more thorough examination in a wider range of tissues is needed to fully confirm these results.  
4.3 Expression analysis in cell lines 
Expression of RGL1 and Ciz1 splice forms were also examined in a range of cell lines (Ad5, 
Skov3, Saos2, A431, Du145, H1299, Hela and McF7 first-strand cDNA was purchased, and U118 
first-strand cDNA was synthesized from RNA, purified from frozen U118 cells) (Fig. 4-3). 
Normalization of cDNA level was performed by PCR with GAPDH and Advantage polymerase, but 
the template amount in U118 still was slightly lower than the rest. The Advantage polymerase was 
used for Ciz1 amplification, but when used on RGL1 splice forms resulted in unspecific bands in 
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H2O. Therefore the Phusion Hot Start polymerase was used on RGL1. PCR on GAPDH using the 
Phusion polymerase was also performed, which surprisingly changed the pattern, and no bands 
were seen in the three cell lines; Skov3, Saos2 and Du145. Therefore the normalization of the cell 
lines is not regarded as completely accurate.  
Fig. 4-3 PCR on cDNA from cell lines. PCR was run using the following primer sets, with expected 
sizes; CizF/M/L (Ciz-for-3 + Ciz-rev-4; 584/500/417 bp), RGL A (RGL-for-1 + RGL-rev-4; 317 bp), 
RGL C/M (RGL-3-for + RGl-rev-4; 416/306 bp), GAPDH (GAPDH-for + GAPDH-rev; 893 bp). 10 µl 
sample was mixed with 5 µl loading buffer, and run on a 1% agarose gel with EtBr, and UV 
photographed. 
The Advantage polymerase was used for amplification of Ciz, and the Phusion hot start polymerase 
was used on RGL1. GAPDH is used for normalizing the cDNA level with the Advantage polymerase, 
but the U118 cell line, has however a lower signal. PCR on GAPDH was also performed using the 
Phusion polymerase, which resulted in a different pattern.  
The expression of Ciz F is clearly higher than Ciz L, in all cell lines examined, and no expression of 
Ciz M is observed. Both Ciz F and L do however seem to be low expressed in U118. The RGL1 splice 
forms appeared to be very low expressed in all tissues, except in U118 where the expression is clearly 
upregulated.  
The expression analysis showed a reproducible, minor upregulation of Ciz F in the Ad5 cell line, 
and a general lower expression of Ciz L than Ciz F. Again the expression of Ciz M seems 
completely absent. Furthermore, the expression of both Ciz F and L appeared very low in the U118 
cell line.  
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The expression pattern of the RGL1 splice forms changed a bit from one experiment to the next, 
making it hard to determine a specific pattern. But one general pattern was though, that all splice 
forms seems very highly expressed in the U118 cell line, and very low in the other cell lines. 
4.4 Cloning of the RGL1 and Ciz1 splice forms 
All splice forms were sought to be isolated from AD tissue, so that any possible alterations in the 
genes would be accounted for in the experiments. Since the template concentration of some of the 
splice forms was very low in AD tissue, cDNA from cerebellum and hippocampus from a normal 
brain was used instead.  
The RGL A, C and Ciz F and M splice forms were amplified by PCR, using mutagenic primers to 
introduce an XbaI site right before the start codon and an XhoI site at the stop codon, as well as 
changing the stop codon into a coding amino acid. The sequence surrounding the startcodon was 
furthermore slightly optimized, to ensure expression of the ORFs. The Ciz L splice form lacking a 
167 bp region in exon 9, was not possible to amplify during the PCR on the full length transcripts, 
so only Ciz F and M (lacking 84 bp of the region) was chosen for further examination.  
The PCR products were gel purified and cloned into TOPO vectors. They were then digested with 
EcoRI to control insert sizes, and the insert ends sequenced to confirm the sequence and a correct 
direction of the insert. Hereafter the TOPO vectors were digested with XhoI and XbaI (Fig. 4-4 A). 
The smaller fragments were gel purified and cloned into pcDNA™6/V5-His A vectors (see 
Appendix III: pcDNA vector maps).  
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The RGL M splice variant was found during investigation of possible up- or downregulation in AD 
tissue. The primers used in the PCR only amplified the region spanning exon 2, 4, 5 of the RGL C 
splice form, producing a PCR product of 417 bp, and the new band appeared to be approx. 300 bp 
(Fig. 4-4 B). TOPO cloning and sequencing of the smaller band, concluded the band to contain 
exon 2 and 5, spanning 306 bp. Since the lacking exon 4 consists of 111 bp, a multiple of three, the 
reading frame does not shift, but rather a small region in the N-terminal end of the translated protein 
is lacking.  
A B
Fig. 4-4 (A) pCR®4-TOPO® vector digest. TOPO vectors with RGL A, C and Ciz F, M inserts were 
digested with XhoI and XbaI, and the smaller fragment excised from the gel, and gel purified. The 
TOPO vectors with RGL C and the RGL M fragment were digested with XhoI and HindIII. (I) this 
fragment contains exon 2 and 5, where (II) contains exon 2, 4 and 5. The digested RGL C vector and 
RGL M fragment were excised and gel purified, and then ligated to create a full RGL M ORF. The 
new TOPO vector with RGL M was then digested with XhoI and XbaI as the rest, and all splice forms 
were cloned into pcDNA™6/V5-His A vectors. (B)  PCR on cDNA from AD tissue from CA1 region of 
hippocampus, normal tissue from hippocampus and a negative control. PCR was run 47 cycles at 
64.4°C, which was necessary to get a band in the AD sample. This shows that the RGL M and C splice 
variants are very low expressed in AD tissue. 
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5’ RACE was performed on double stranded Marathon cDNA from hippocampus, using the AP1 
primer and the RGL-4-rev primer which is placed in exon 5. Nested RACE was hereafter carried 
out using the AP2 primer and a RGL1 specific RACE primer; 5’ RACE, which is placed on a 
region spanning both exon 2 and 5 (Appendix II: Primers).  
A B
Fig. 4-5. (A) Illustration of the 5’RACE on RGL M (B) Illustration of the exon structure of RGL M, 
which is assumed to have the same 3’ end as RGL C. 
The 5’ RACE showed that the new RGL M variant like RGL C, had exon 1 upstream of exon 2. 
Since exon 4 consists of a multiple of three base pairs, the lacking exon 4 does not create frame 
shift. Due to the identical 5’ end of RGL C and M as well as the intact ORF (minus the exon 4 
region), the 3’ end of RGL M was assumed also to be identical (Fig. 4-5). 
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The TOPO vector with the RGL M fragment and RGL C was digested with XhoI and HindIII, and 
the RGL M fragment ligated with the TOPO RGL C vector lacking exon 2,4 and 5 (Fig. 4-6). This 
new RGL M TOPO vector was then also digested with XhoI and XbaI, and cloned into the 
pcDNA™6/V5-His A vector.  
Fig. 4-6. 
Construction of 
TOPO vector with 
RGL M. The TOPO 
vector with RGL C 
and RGL M 
fragment was 
digested with XhoI 
and HindIII. Then 
the vector 
containing the rest 
of RGL C was 
ligated with the cut 
out RGL M 
fragment, to create 
an RGL M ORF.  
The various pcDNA™6/V5-His A vector constructs were then transformed into competent cells, 
and microscale plasmid preparations were made. The entire ORF was then sequenced and large 
scale plasmid preparations as well as glycerol cultures made. The correctness of the sequences was 
investigated by using BLAST3 to compare them with already known sequences.  
4.5 TNT-coupled protein expression 
To determine if the constructs are transcribed into the intended proteins, and have the V5 epitope 
attached to the C-terminal end, a TNT-coupled transcription/translation was carried out (Fig. 4-7). 
The incorporation of radioactive labeled methionine will only show the size of the proteins, 
3 http://www.ncbi.nlm.nih.gov/blast/ 
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including the 14 aa V5 epitope, so whether the V5 epitope is correctly translated cannot be 
concluded from this experiment.  
Fig. 4-7 TNT coupled transcription/translation of RGL1 and Ciz1 constructs. Proteins with 
incorporated [S35]-Methionine were run on a 4-12% SDS gel, transferred to a ECL 
membrane, dried and finally exposed in a phosphorimager cassette. (A) First TNT blot 
showed relatively correct sizes of proteins for all splice forms, except Ciz F. The protein sizes 
did not follow the standard PAGE marker, but compared to each other, the sizes appear 
correct. The expected sizes including the V5 epitope were; RGL C 91.5 kDa, RGL A 87.7 
kDa, RGL M 87.5 kDa, Ciz F 102 kDa, and Ciz M 99 kDa. Ciz F, which should result in the 
largest protein, is clearly much smaller than all the others. (B) After site-directed 
mutagenesis a new TNT-coupled transcription/translation was carried out on the two Ciz1 
constructs. Now the Ciz F construct translates into a larger band than Ciz M, and appears to 
have the correct size.  
All proteins, except for the Ciz F construct, appeared to have the correct size, although the bands 
were a bit off compared to the standard PAGE marker. Furthermore more than one band appeared 
in all lanes. The size of the Ciz F construct was too small compared to the other bands (Fig. 4-7 A) 
and therefore sequencing of the entire ORF was carried out. The sequencing revealed numerous 
mutations in the sequence compared to the NCBI obtained sequence (NM_012127). These 
mutations are probably just differences between individuals in a population, and most of these only 
change a single amino acid in the translated protein. But at bp no 1823 in the ORF (bp no 2029 in 
NM_012127) the substitution results in a stop codon (probably caused by the polymerase during 
PCR) which may cause the unexpected small protein size. Since this stop codon results in loss of 
the C terminal end of the protein, the V5 epitope is also missing. Therefore site-directed 
mutagenesis was carried out, to re-establish the original ORF. 
A new TNT-coupled in vitro translation was carried out (Fig. 4-7 B) to confirm that the entire ORF 
was now translated, and that the V5 epitope was included. Furthermore sequencing of the other 
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constructs was also carried out to eliminate any other possible mutations, resulting in altered 
proteins.
4.6 Whole cell protein extraction 
Since the TNT-coupled expression only showed the approximate sizes of the proteins, it is not 
known with certainty that the V5 epitope is attached to the protein or even translated correctly. 
Therefore a whole cell extraction was carried out using transfected murine N2A cells, and western 
blots were carried out. This will furthermore give an idea of how much protein is being expressed 
from the constructs. For a negative control the empty pcDNA™6/V5-His A vector was included, 
and for a positive control a construct containing NDRG2 was included.  
Cell lysates were analyzed by western blotting (see 3.3.3.6) and proteins detected by incubation 
with mouse V5 antibody and then anti-mouse antibody. The blots were hereafter stripped with 0.2 
M NaOH and then incubated with mouse -Actin and anti-mouse antibodies, to control loading 
amounts.
Fig. 4-8 Western Blot of whole cell extracts. (A) Expression of the different RGL1 constructs in N2A 
cells. The empty pcDNA vector is used as a negative control and NDRG2 as a positive control. The 
bands appear to have the correct size compared to each other, but not compared to the protein 
ladder. The expression of RGL C and M seems higher than RGL A, compared to the -Actin loading 
control. (B) Expression of the two Ciz1 splice forms, as well as the empty vector. The two Ciz1 
constructs seem to be equally expressed. 
The attachment of the V5 epitope, by insertion of the various RGL1 and Ciz1 ORFs into the vector 
in frame with the epitope, has clearly worked in all constructs. The two RGL1 variants RGL C and 
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M have a much higher expression than RGL A (Fig. 4-8 A), which is probably due to the different 
ORF start sites. The Ciz1 splice form constructs seem to be more equally expressed (Fig. 4-8 B). 
Like in the TNT coupled expression, the sizes do not appear correct, compared to the standard 
PAGE protein ladder, but compared to each other they seem correct. Furthermore only one band is 
seen in each lane, which concludes that the multiple bands in the TNT coupled expression, was a 
cause of the artificial environment.   
4.7 Cell fractionation 
This method of fractionating cells is adapted from (He et al., 1990;Farley et al., 2006) and was 
originally developed as a method for studying the core filaments of the nucleus, often referred to as 
‘the nuclear matrix’. The method consists of various steps that first rupture the membranes to 
release all soluble proteins, and hereafter extracts bound proteins by different salt solutions and 
enzymes. The fractionation steps result in four fractions; a fraction of all soluble proteins (both 
cytosolic and nuclear), a fraction of chromatin bound proteins released by digestion with DNase, a 
chromatin bound  fraction released by a 2 M NaCl concentration, and finally all proteins firmly 
bound to the nuclear matrix.  
It has been shown that the replication origins are attached to the nuclear matrix in late G1 phase, 
and then dissociate after replication initiation (Djeliova et al., 2001). Furthermore, (Radichev et al.,
2005) performed an in vitro analysis of the chromatin depleted nuclear matrix, and showed that the 
proteins still remaining bound were able to initiate DNA replication. The purpose of this method 
was to detect if Ciz1 is bound to the chromatin or the nuclear matrix, since this could assist in 
verifying the possible role of Ciz1 as a replication factor. The method was also performed on RGL1 
transfected cells, to investigate the localization of the RGL1 protein. All results were reproduced 
minimum two times and representative results shown. Note that when comparing the fractions, 
variable volumes have been used for dissolving the pellet during the procedure; soluble 1X, 
chromatin DNase 1.3X, chromatin NaCl 1X, nuclear matrix 0.25X.  
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4.7.1 Ciz1 transfected cell fractionation
Fig. 4-9 Western blot of V5-tagged Ciz F and M in cell fractions; soluble proteins, chromatin bound 
proteins (DNase fraction and NaCl fraction) and nuclear matrix bound proteins. The proteins Lamin, 
-Tubulin and Histone H3 are released in different fractions, and can therefore be used for controlling 
the purity of the fractions. (A) The fractions show that Ciz F is present in both the soluble fraction, 
bound to chromatin and also the nuclear matrix. (B) Ciz M is also present in the same fractions, but 
only a very week signal was detected in the nuclear matrix.  
The two Ciz1 isoforms; Ciz F (Fig. 4-9 A) and Ciz M (Fig. 4-9 B) appear to have a similar 
expression pattern, being present in the soluble, chromatin DNase and nuclear matrix fraction. Ciz F 
does however have a much stronger band in the nuclear matrix than Ciz M, compared to the other 
fractions. Since the soluble fraction contains both cytosolic and nuclear proteins, it is not possible to 
tell whether Ciz1 is located solely in the nucleus or is both cytosolic and nuclear. 
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4.7.2 RGL1 transfected cell fractionation
Fig. 4-10 Western blot of V5-tagged RGL A, C 
and M in cell fractions; soluble proteins, 
chromatin bound proteins (DNase fraction and 
NaCl fraction) and nuclear matrix bound 
proteins. The proteins Lamin, -Tubulin and 
Histone H3 are used for purity controls. RGL A 
(A), RGL C (B) and RGL M (C) all appear to be 
present in the soluble fraction as well as the 
nuclear matrix.  
All RGL1 isoforms appear in the soluble fraction as well as the nuclear matrix fraction (Fig. 4-10).
The presence in the soluble fraction is not surprising, since RGL1 supposedly interacts with Ral, or 
Ras effector proteins located near the cellular membrane. But the presence of RGL1 in the nuclear 
matrix fraction is surprising. No results presented so far has pointed to a role for RGL1 in the 
nucleus, or shown RGL1 to be located there.  
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4.8 Immunofluorescence staining 
To elaborate on the results obtained by the cell fractionation method, immunofluorescence staining 
of murine N2A neuroblastoma cells transfected with the various splice forms was carried out.  
4.8.1 RGL1 transfected cells
The cells transfected with the RGL A, C and M pcDNA vector, as well as the empty vector were 
stained with mouse V5 and Alexa Fluor® 488 anti-mouse antibodies (emits green light) and then 
DAPI (emits blue light) which binds strongly to the minor groove of genomic DNA (Fig. 4-11). 
A
B
C
Fig. 4-11. N2A cells were grown on coverslips and 
transfected with RGL1 constructs. Cells were then fixed with 
cold methanol and stained with mouse V5-antibodies, and 
then mouse-antibodies and finally the coverslips were 
mounted on microscope slides with DAPI. All RGL1 
isoforms; RGL A (A), RGL C (B) and RGL M (C) localized 
in the cytoplasm and neurites and cells with highly expressed 
protein appeared to have longer and more branched 
neurites. (D) Control: Cells transfected with the empty 
pcDNA6/His A vector and stained with mouse V5 and anti-
mouse antibodies and DAPI. Some cells differentiates 
spontaneously, but has very short and few neurites. 
 D
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All the examined RGL1 proteins seem to be present in the cytosol and in all neuritic branches, of 
cells with highly expressed amounts of protein. No signal was found in the nucleus, which does not 
agree with the results from the western blots, where RGL1 was found to be present in the nuclear 
matrix. Though it was difficult to identify neurites from individual neurons, a specific pattern was 
found; Compared to the non-transfected cells, the RGL1 transfected cells had thicker, longer and 
much more branched neurites (see Fig. 4-11 B and C), revealing that RGL1 could have a role in cell 
differentiation or neurite growth. Furthermore, the RGL A isoform seemed to induce thinner and 
less branched neurites than the RGL C and M isoforms, and the cytoplasmic volumes of the RGL C 
and M transfected cells seemed larger than those of the RGL A transfected cells. A more elaborate 
study would need to be carried out though, to fully validate this. The difference could however be 
the effect of a general lower expression of RGL A than RGL C and M. 
The transfected cells with less expressed protein showed the same pattern; having more signal 
within the cytoplasm than the neurites, and no signal in the nucleus, but the neurites seemed thinner. 
Another difference between the cells with highly expressed protein and less expressed protein was 
that high expression led to more branched and thicker neurons compared to the cells with low 
expression. This further emphasizes the possibility that RGL1 is involved in neurite-branching. 
Sometimes the neurites even seemed to form big clumps (Fig. 4-11 C, white arrows).  
The RGL1 proteins are localized in the neurites, which could indicate that RGL1 has a function in 
the growth cones e.g. in the skeleton structure. Since -Tubulin is the main component of the 
cytoskeleton, a possible co-localization of RGL1 and -Tubulin was investigated, by co-staining 
with -Tubulin and V5 antibodies (Fig. 4-12).  The -Tubulin antibody was produced in mouse 
cells, and therefore rabbit V5 antibody was used for these experiments. 
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C
Fig. 4-12. Immunofluorescence staining of RGL1 transfected cells with rabbit V5 and -Tubulin 
antibodies and DAPI. (A) The majority of the RGL A transfected cells expressed very little protein 
and the protein was concentrated in clumps in the cytoplasm. Cells with highly expressed protein 
did however have the same pattern as the staining with mouse V5- antibodies; the protein was 
localized in all cytoplasm and neurites. (B) RGL C transfections and (C) RGL M transfections 
showed the same pattern as RGL A, but RGL M had a much higher rate of cells with highly 
expressed protein. (D) RGL1 control, with RGL C as a representative. The cells were stained with 
rabbit V5- antibodies and then both anti-mouse and anti-rabbit antibodies. The aggregate-like 
pattern of RGL1 is also seen here, which concludes that it cannot be caused by an interaction 
between the -Tubulin and rabbit V5 antibodies. (E) RGL M transfected cells with highly 
expressed protein stained with rabbit V5- antibodies. 
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This staining did surprisingly showed a completely different pattern than the staining with mouse 
V5-antibodies. The transfected cells with a low amount of expressed protein formed clumps next to 
the inner membrane. The clumps were found throughout all RGL1 transfections, indicating that the 
pattern is not caused by an error in a single transfection, and it is not specific to a particular protein 
isoform. Furthermore controls with staining of RGL1 transfected cells with rabbit V5- antibodies 
and both anti-rabbit and anti-mouse antibodies resulted in the same pattern, concluding that the 
clumps are not caused by a reaction between the V5 and -Tubulin antibodies. The results from the 
mouse V5-antibody stainings are regarded as the most credible since the antibody has been tested in 
the various western blots. Therefore the rabbit anti-V5 stainings are regarded as an artefact probably 
caused by unspecific binding and changes in the growth conditions during transfection/expression 
of the constructs. To confirm these assumptions, the cell stainings will have to be repeated.  
The cells with highly expressed protein did however have the same pattern as before, with highly 
branched neurites. None of the RGL1 variants did however seem to co-localize with -Tubulin.
4.8.2 Ciz1 transfected cells
Ciz1 transfected cells were also stained with mouse V5-antibody and Alexa Fluor® 488 goat anti-
mouse antibody and then DAPI (Fig. 4-13).  
C
Fig. 4-13. Immunofluorescence staining of Ciz1 transfected cells with mouse anti-V5 and DAPI. (A) 
Ciz F appeared in a dot like pattern, localized in cytoplasm as well as nucleus (C) (N, nucleus). (B) Ciz 
M is localized only in the nucleus in a diffuse pattern. 
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The Ciz1 transfected cells revealed an interesting pattern; as expected Ciz F appeared as speckles, 
but with changing patterns. Sometimes seeming only present in the cytosol, sometimes present only 
in the nucleus and other times located throughout the cell (Fig. 4-13 A and C). The Ciz M 
transfected cells had a completely different pattern. Here the protein appeared diffusely in the 
nucleus, and no signal was seen in the cytoplasm (Fig. 4-13 B).  
The cells were also stained with rabbit V5-antibody together with mouse -Tubulin antibody and 
DAPI (Fig. 4-14), like the RGL1 transfected cells. Here the pattern seemed identical to the mouse-
V5 antibody stainings, concluding that the different pattern of the RGL1 stainings must be due to a 
specific interaction of RGL1. 
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B
Fig. 4-14. Immunofluorescence staining of Ciz1 transfected cells. (A) Ciz F is localized in both 
cytoplasm and nucleus. (B) Ciz M did not form the speckles, but was localized in the nucleus in a 
diffuse pattern. (C) The pattern of Ciz F varied from speckles solely in the nucleus, the cytoplasm 
or throughout the cell. The majority of the transfected cells did not have any neurites, and in the 
few that did Ciz F or M was not localized here.  
Besides the clear differences in localization of the RGL1 and Ciz1 proteins, the morphology of the 
cells also seemed quite different. As mentioned the RGL1 transfected cells with highly expressed 
protein, were very large due to the extensive branchings of the neurites, but the cytoplasm also 
seemed larger. The Ciz1 transfected cells, both Ciz F and M, seemed relatively small, with no 
branches at all or very few, small and unbranched.  
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5 Discussion 
5.1 Possible upregulation of RGL1, Ciz1 and Ephrin A3 in AD tissue 
The three genes; RGL1, Ciz1 and Ephrin A3, were chosen to be investigated, on basis of the 
preliminary experiment showing upregulation of all three genes on mRNA level. The examination 
of possible up- or downregulation by PCR, did not completely confirm the results from the slot blot. 
Neither examined Ephrin A3 splice variants appeared to be upregulated, nor did RGL A or Ciz F, 
and Ciz M seemed completely absent in both tissues. Ciz L was the only spliceform which seemed 
slightly upregulated, though a more elaborate experiment is needed to confirm this. RGL C and M 
on the other hand showed quite the opposite; they appeared highly downregulated in AD or 
completely absent.  
A possible explanation for the divergence between these experiments is that the probe from the slot 
blot was contaminated by the presence of genomic DNA. Thereby unspecific binding could 
contribute to the signals on the slot blot. Contamination of genomic DNA in the PCRs performed in 
this project is not likely, since the primers were designed to amplify a region spanning two exons or 
more and the inclusion of introns in the PCR product would be easy detectable on the agarose gel. 
Another possibility is unspecific binding of probes due to similar domains. For example RGL1 has 
highly conserved regions compared to other Ras-like proteins, and the signals on the slot blot could 
therefore be disturbed by cDNA from similar genes. Also, the slot blot showed a general picture of 
all possible splice forms, and the splice variants not investigated here could have contributed to the 
previous results. Therefore the results from the PCRs in this project seem more plausible, though 
further experiments remain to be conducted to confirm the results. 
5.2 PCR on selected tissues and cancer cell lines 
PCR was performed on cDNA from four normal tissues; hippocampus, cerebellum, liver and colon, 
as well as ten cancer cell lines which included one brain cancer, i.e. glioblastoma (U118). Ciz1 
expression was only slightly downregulated in liver and colon, whereas all RGL1 splice forms 
seemed more clearly downregulated in liver and colon, compared to the brain tissues; cerebellum 
and hippocampus. This indicates that RGL1 is tissue specific regulated.  
In contrast the PCR on cancer cell lines, seemed to indicate that both Ciz1 splice forms were 
relatively low expressed in the U118 cell line, compared to all RGL1 splice forms, which had a very 
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high expression in U118, compared to the other cell lines. These results seem to indicate that RGL1 
is upregulated in glioblastoma, which supports the theory of RGL1 being involved in cell 
proliferation.
These results corresponds well with the northern blot of Ciz1 mRNA expression performed by 
(Warder and Keherly, 2003) showing a lower expression in liver, compared to brain. The northern 
blot of RGL1 expression by (Sood et al., 2000) is less useful for comparison, since it is not possible 
to tell, what are stronger bands and what are different splice forms, and no loading control is shown. 
The blot does however clearly show RGL1 to be present in almost all tissues, but whether this is 
due to the presence of other RGL1 splice forms than the ones investigated in this project, or other 
factors is not possible to conclude.  
5.3 Protein expression 
To ensure a correct translation of the various constructs, and having the V5 epitope attached, a TNT 
translation was carried out, followed by expression in murine N2A neuroblastona cells and western 
blot of whole cell protein extraction. The TNT coupled in vitro transcription/translation results 
showed multiple bands in many of the samples, which could be thought of as effects of 
posttranslational modifications. However, since the proteins were expressed in an in vitro
experiment, such modifications do not occur. Instead this is probably the effect of using a 
bacteriophage polymerase in an artificial environment where translation easier initiates at other start 
sites and thereby produce variable length proteins. Another explanation for the multiple bands could 
be breakdown of the proteins by proteases, due to inefficient protease inhibition in the samples.  
The whole cell protein extraction gave a much clearer image of the protein sizes, now only resulting 
in one band per lane. The actual sizes of the proteins were difficult so determine, since the 
prestained protein ladder can only be used to give an approximately size, but compared to each 
other the proteins seemed to have the correct size.  
The western blot of the whole cell extraction showed that the two RGL1 splice forms with 
startcodon in exon 2 (RGL C and M), have a higher expression than RGL A, (with startcodon in 
exon 3). The sequence surrounding the start codon was however optimized a bit to ensure a good 
translation, and the sequence surrounding the start codon in the RGL C and M variants, had a higher 
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conservation compared to the Kozak sequence (CC(A/G)CCATGG). This is probably the reason 
for the different expression levels. 
The cloning of the Ciz L splice variant was very difficult, and due to lack of time, it was decided to 
proceed only with Ciz F and M. The only difference between the Ciz M and L splice forms is that 
Ciz M lacks a smaller part of exon 9, than the Ciz L variant, but the region still interrupts the second 
glutamine rich domain. It is however quite remarkable that the Ciz M variant was not present in any 
of the performed PCRs on AD tissue, the selected tissues or the cancer cell lines. An explanation for 
this must be that the expression of this variant is extremely low, and that it was a mere chance it 
was cloned.  
5.4 Cellular localization of Ciz1 
Cell fractionation and immunofluorescence staining of transfected N2A cells were performed to 
analyze the localization of Ciz1. The cell fractionation showed Ciz1 to be present in the soluble, 
chromatin and nuclear matrix fraction, which indicates that Ciz1 in bound to the nuclear matrix, as 
well as chromatin.  
During the time the cellular localization experiments were carried out, an article by (Ainscough et 
al., 2007) was published showing some of the same results as presented in this rapport. The 
experiments were however carried out using the murine Ciz1 variant, which has about 70% amino 
acid sequence homology to human Ciz1, as well as a smaller variant, lacking the first poly 
glutamine domain and part of the second. Like in this project, they also investigated the possible 
binding of Ciz1 to the nuclear matrix which could further confirm its proposed a role as a 
replication factor.  
Ainscough and coworkers showed that Triton-X 100 fail to release Ciz1 proteins, which they 
conclude indicates that Ciz1 proteins are not a soluble protein in the cell, but instead anchored at 
some structure (Fig. 5-1 A). This does not correspond completely with the results from this project, 
where both Ciz1 isoforms were present in the soluble fraction, treated with Triton X-100. However, 
there were small differences in the used buffers, as well as a difference in the Triton-X 
concentration; they used 0.2% where a 0.5% concentration was used in this project. This more 
rough treatment of the cell could possibly have caused some Ciz1 proteins to be released into the 
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soluble fraction, or it simply reflects that Ciz1 proteins are not always anchored in the cell. Another 
explanation could be a difference between the mouse and human Ciz1 homologue, though the 
domains are highly conserved.  
A B 
Fig. 5-1. Western blot of cell fractions from 
mouse Ciz1 transfected NIH3T3 cells. (A) Cell 
fractions of whole cell (T), and two Triton-X 
treated fractions; a soluble and a pellet. (B) 
Cycling, S-phase arrested and G0-phase 
NIH3T3 cells were fractionated by treatment 
with 0.5 M NaCl, washed twice and then 
treated with 2.0 NaCl. Western blot on these 
fractions as well as the pellet (P) were then 
carried out. Modified from (Ainscough et al.,
2007). 
Ainscough et al also examined a possible coherence  between the cell cycle state and the expression 
of Ciz1, by fractionating cycling cells as well as cells arrested in S and G0 phase (Fig. 5-1 B). The 
cells were treated with 0.5 M NaCl solution, washed twice and then a 2.0 M NaCl solution, and then 
the pellet was dissolved in UREA. They did not find any clear variations corresponding to the cell 
phases, but the smaller isoform appeared to be most resistant to the salt extractions. They conclude 
that Ciz1 appears to bind to non-chromatin structures, but since their experiments do not reveal if 
Ciz1 possibly binds chromatin, they cannot rule it out. The experiments performed in this project do 
however indicate that Ciz1 also binds chromatin, though a more elaborate experiment is needed to 
fully confirm this.  
Furthermore the results from this project seem to indicate that the full length Ciz F variant was 
more resistant to the extraction procedures than the Ciz M variant, when comparing the relative 
amounts in the fractions. This is quite the opposite of the results by (Ainscough et al., 2007), which 
found the small mouse Ciz1 isoform to be most resistant to the extraction, but the difference is 
likely to be caused by the many different factors between these experiments. They also investigated 
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different constructs with various deletions for their resistance of to the salt extractions, and 
postulate that the Ciz1 protein binds to the nuclear matrix through the C-terminal end.  
In this project the immunofluorescence staining of the Ciz1 transfected cells showed that Ciz F 
localized to both the cytoplasm and the nucleus, but in a speckled pattern. It is however very 
difficult to completely place the Ciz F isoform in the nucleus, since the microscope only can 
photograph the entire cell. Therefore proteins located directly above or below the nucleus, can 
mistakenly be thought to be placed in the nucleus. Using a confocal microscope to view single 
layers of the cells would be more precise for locating the proteins. The presence of Ciz F in the 
nucleus does fit well with the results from the cell fractionation experiments, showing that Ciz1 
bind to the nuclear matrix. The Ciz M variant examined in this project, which lacked only a part of 
the second poly glutamine domain (see Fig. 2-3 for the Ciz1 domain structure), showed a disruption 
of the speckled pattern, and instead a diffuse localization in the nucleus was found.  
(Ainscough et al., 2007) also carried out immunofluorescence staining, but used NIH3T3 cells and 
GFP-tagged Ciz1. They showed a dotted appearance of the full length Ciz1 variant, where the 
smaller splice variants of mouse Ciz1 formed fewer and larger speckles. Their results from the full 
length Ciz1 variant closely resemble the results from this project, but the pattern of Ciz M in this 
project does not however correspond with the results from (Ainscough et al., 2007). This could be 
due to the deletion of both domains, their use of GFP tags, the use of different cells or simply a 
difference between mouse and human Ciz1.  
The experiments in this project showed a rather profound difference in the immunofluorescence 
stained Ciz1 variants, which indicates that the small section in exon 9 (aa 1421-1505) has great 
impact on the dotted appearance and localization of the Ciz1 protein. Since this region is also 
lacking in the Ciz L variant it is postulated that the appearance and localization of Ciz L would 
resemble that of Ciz M. The morphology of N2A cells did not appear to be affected by the Ciz1 
expression, and no difference was observed between the two isoforms. All cells resembled the 
untransfected controls, being very small and having none or few unbranched neurites.  
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5.5 Cellular localization of RGL1 
Cell fractionation and immunofluorescence staining was also carried out on RGL1 transfected N2A 
cells. The cell fractionation experiments showed all three RGL1 splice forms to be present in the 
soluble fraction, as well as the nuclear fraction. The immunofluorescence staining did however only 
place RGL1 in the cytosol and neurites, so perhaps the nuclear fraction, which may contain ‘heavy 
leftovers’ which were not possible to remove in the other fractions could contain RGL1 protein 
aggregations. The method should perhaps therefore be thought of as an indicator of possible binding 
to these structures, which can then be further investigated by other methods. 
The immunofluorescence staining of the RGL1 transfected cells revealed a significant effect of 
RGL1 on the cell morphology, by promoting quite extensive neurite sprouting. Both the number of 
neurites, as well as their number of branches was clearly enhanced compared to the untransfected 
cells. Though the N2A cells seem to have tendencies to spontaneous differentiation, the results from 
the RGL1 transfected cells clearly differ from the untransfected. The ability to induce 
differentiation in neurons supports the suggested role of RGL1 as a Ras activating protein. Since the 
NGF receptor signaling occurs through the Ras pathway, it is very likely that RGL1 could affect 
this by increasing the amount of active Ras, and thereby enhancing the signaling to differentiation 
of the cell. The suggested function of RGL1 in the NGF-Ras-MAP pathway is however not definite, 
since N2A is a cancer cell line, and the pathway thereby could be altered. Some neuroblastoma cells 
differentiate in vitro when stimulated by NGF, but die in its absence, while others establish 
autocrine pathways to promote cell survival, by expressing their own growth factors, reviewed in 
(Maris and Matthay, 1999). The used neuroblastoma cell lines do not depend on NGF stimulation 
for survival, which strongly indicates an altered pathway. Therefore further experiments are needed 
to confirm this suggested role of RGL1.  
Another morphological effect of RGL1 on the N2A cells was that the cytoplasmic volume of the 
RGL1 transfected cells appeared much larger than that of the untransfected and Ciz1 transfected 
cells. Furthermore the RGL C and M transfected cells appeared to have larger cytoplasmic volumes 
than RGL A. This could however just be an attempt by the cell to cope with the large amounts of 
expressed protein, and since RGL A has a general lower expression of protein this could explain the 
difference between the RGL A and RGL C/M transfected cells.  
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6 Conclusion 
6.1 AD/ normal tissue 
The examination of RGL1, Ciz1 and Ephrin A3, did not confirm the possible upregulation on 
mRNA level in AD tissue from the slot blot by (Mitchelmore unpublished) (Fig. 2-2). Only Ciz L 
seemed slightly upregulated. In contrast, the RGL1 variant RGL C was almost completely absent in 
AD tissue and the new RGL M variant appeared to have a very low expression in AD.  
6.2 Tissues and cell lines 
The examination of mRNA levels in tissues showed that all RGL1 splice forms were slightly lower 
in liver and colon compared to the brain tissues. Only a minor downregulation of expression in liver 
was observed for both Ciz1 variants. PCR on the selection of cell lines did however give a more 
interesting result. All RGL1 splice variants seemed very high expressed in the glioblastoma cell 
line, and relatively low expressed in all other cell lines. In contrast both Ciz1 splice forms seemed 
to have a low expression in the glioblastoma cell line, and a slightly elevated level in MCF-7 breast 
cancer cell line, compared to the other examined cell lines.  
6.3 The cell fractionation 
The cell fractionation experiment showed that both the Ciz F and M isoform were present in the 
soluble, chromatin and nuclear matrix fraction, and thereby it is suggested that Ciz1 does not only 
bind to the nuclear matrix, but also directly to chromatin. A hypothesis for this could be that Ciz1 
are bound in a replication complex, which is attached to both the nuclear framework and the 
chromatin, and that some of the protein did not resist the harsh extraction method, and therefore was 
washed out in the soluble fraction.  
The RGL1 protein also appeared in more than one fraction; the soluble and the nuclear matrix. The 
presence in the soluble fraction corresponds well with the hypothesis that RGL1 is a Ras effector 
protein, which functions in the cytosolic pathway from the outer membrane to the inner. The 
presence in the matrix fraction does not correspond with the immunofluorescence staining, and is 
therefore regarded as an effect of the extreme amounts of expressed protein in the cells. 
6.4 Localization and effects on cell morphology in neuroblastoma 
The immunofluorescence staining showed that the two examined Ciz1 isoforms localized to 
different sites in the cell; Ciz L only localized in the nucleus in a diffuse pattern, whereas Ciz F was 
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found both in the nucleus and the cytoplasm in a varying, speckled pattern. The morphology of the 
Ciz1 transfected cells resembled the untransfected dividing cells, which indicates that Ciz1 perhaps 
keeps the cell in the cell cycle.  
The RGL1 transfected cells had a completely different morphology. The cells appeared highly 
differentiated, with multiple, relatively long and branched neurites, with RGL1 proteins present in 
all neurites and cytoplasm, but not in the nucleus. This indicates that RGL1 is capable of inducing 
differentiation in neuroblastoma.  
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8 Further Experiments 
The precision of using PCRs for investigation of possible altered mRNA expression is ambiguous, 
especially when a high number of cycles are run. This was however necessary since the amount of 
Ciz1 and RGL1 in the tissues was very low. The results also varied some during the experiments, 
and quantitative-PCR could probably give a more accurate result, since the exact time of saturation 
can be measured.  
A possible up- or downregulation in protein levels of Ciz1 and RGL1 in AD tissue would also be 
interesting to investigate, as well as in different tissues and cell lines. The U118 glioblastoma cell 
line would be particular interesting to examine, since these experiments showed a possible altered 
mRNAexpression. 
The used cell fractionation method does not distinguish between nuclear and cytosolic proteins, but 
only soluble and bound proteins. Ideally the method could contain a fifth fraction, separating the 
cytosolic soluble proteins from the nuclear. This could be done by adding a step at the start, using a 
more gently cell lysis, so only the outer membrane is affected, and centrifugation with fewer RPM. 
Due to the time it would take to design and optimize the method to contain this extra fractionation, 
it was not possible to include in this study.  
To elaborate on the result showing RGL1 to be able to induce differentiation in neuroblastoma, a 
quantification of the length, numbers and side-branches of neurites would be interesting to carry 
out. Since the N2A cells are not dependent on stimulation by NGF, the NGF-Ras pathway can not 
be functioning correct, and therefore the function of RGL1 could be altered in normal cells. 
Therefore a study on non cancerous cells would be ideal, as well as human cells, to insure that the 
same effect is seen here. 
To elaborate on the suggested function of Ciz1 to bind replication complexes, it would be 
interesting to carry out a yeast two hybrid assay to find possible interaction partners.  
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10 Appendix I: Abbreviations 
AA Amino acid HD Huntington Disease 
AD Alzheimer’s Disease HSF Heat shock factor 
AMP Ampicillin  Htt Huntingtin gene 
APOE Apolipo protein E MAP Mitogen activated protein kinase  
APP Amyloid precursor protein MEK MAPK/ERK kinase 
BSA Bovine serum albumine mRNA Messenger ribonucleic acid 
BSE Bovine spongiform encephalopathy NDRG2 N-myc downstream regulated gene 2 
CA Cornu amonis NFT Neurofibrillary tangles 
Cdc2 Cell division cycle 2 PAGE Poly acrylamide gel electrophoresis 
CDK Cyclin dependent kinase PCR Polymerase chain reaction 
cDNA Copy deoxyribonucleic acid PBS Phosphate buffered saline 
CDX-1  Caudal type homeo box 1 PrP Prion (proteinatious infectious 
particle) 
CSK Cytoskeletal buffer PVDF Polyvinylidene fluoride 
Ciz1 Cip interacting zinc finger protein 1 RACE Rapid amplification of cDNA ends 
dg Dentate gyrus RGL1 Ral guanine dissociation stimulator 
like 1 
DMEM Dulbecco’s modified Eagles medium RPM Rounds per minute 
EDTA Ethylenediamine tetraacidic acid SDS Sodium dodecyl sulphate 
EGTA Ethylene glycol tetraacidic acid TBP TATA binding protein 
ERE Estrogen responsive element TF Transcription factor 
ERK Extracellular signal-regulated kinase TNT Transcription and translation 
EtBr Ethidium bromide trkA Tyrosine kinase A 
FBS Fetal bovine serum   
GAPDH Glyceraldehyde 3-phosphate 
dehydrogenase 
GATA-1 GATA binding protein 1   
GDP Guanine di-phosphate   
GDS Guanine nucleotide dissociations 
stimulator 
GEF Guanine exchange factor   
GFAP Glial fibrilar acidic protein   
GTP Guanine tri-phosphate   
81
11 Appendix II: Primers 
Primer Specific use Sequence 5’-3’ 
(Primer introduced mutations are in bold; start codon 
and introduced restriction enzyme sites are 
underlined) 
Position NCBI acc. No Res. Site 
intro. 
Eph-rev-2  TCTAGAGGAGGCCAAGAACGTCATGAGGAAG 790-760 NM_004952 XbaI 
Eph-for-3  CCTGCACTGGAAGTGTCTGAGGATG 529-553 NM_004952  
Ciz-for-1  CTCGAGCCACCATGTTCAGCCAGCAG 193-218 NM_012127 XhoI 
Ciz-rev-2  TCTAGACCTTTTGAGGCGGGTTGAGCG 2903-
2877 
NM_012127 XbaI 
Ciz-for-3  GTACCGAAACAGACACAGACACCAGAC 1068-
1094 
NM_012127  
Ciz-rev-4  AACCACAACTGGTGTTTGCTCTGGAG 1652-
1627 
NM_012127  
RGL-for-1  CTCGAGTGACCATGAAATTGCTTTGGCAAGCT 168-199 AF186779 XhoI 
RGL-rev-2  TCTCTAGAGAGGGTGATTTTGCTGTGTCTG 2490-
2461 
AF186779 XbaI 
RGL-for-3  CTCGAGCACCATGGAGGTGAAACCTGTG 440-468 AF186780-ADvar9 XhoI 
RGL-rev-4 PCR/5’RACE CTGTACGTTGAAAGAAAGATGCTGATATAG 756-727 AF186780-ADvar9  
GAPDH for  TGAAGGTCGGAGTCAACGCATTTGGT 65-90 BC001601  
GAPDH rev  CATGTGGGCCATGAGGTCCACCAC 1074-
1024 
BC001601  
GFAP for  TGACCCTCTCCACCCCATAGTGAC 2562-
2585 
NM_002055  
GFAP rev  CTAATCTTCAGGGCACTGCTGCTG 2986-
2963 
NM_002055  
RGL-nested  5’ RACE GTCCCCTTCAACCTCCTCTG    
Ciz-mut-for Site.dir.mut. CCAGCAGGAGTTCCAGGACCACATGTCG 2015-
2042 
NM_012127  
Ciz-mut-rev Site.dir.mut. GGTCGTCCTCAAGGTCCTGGTGTACAGC 2015-
2042 
NM_012127  
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RGL A 
1+4: 317 bp 
1+2: 2323 bp 
RGL C 
3+4: 416 bp 
3+2: 2316 bp 
RGL M 
3+4: 306 bp 
3+2: 2427 bp 
Ciz F 
3+4: 584 bp 
1+2: 2711 bp 
Ciz M 
3+4: 500 bp 
1+2: 2627 bp 
Ciz L 
3+4: 417 bp 
1+2: 2543 bp 
Ephrin 
F
3+2: 261 bp 
Ephrin 
L
3+2: 196 bp 
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12 Appendix III: pcDNA vector maps 
pcDNA RGL A
7453 bp
6xHis
Amp(R)
Bsd(R)
V5 epitope
RGL A
SV40 pA
BGH pA
BGH reverse primer
CMV forward primer
T7 primer
V5 reverse primer
CMV promoter
SV40 early promoter
bla promoter
EM7 promoter
T7 promoter
f1 origin
pUC origin
XbaI (3301)
XcmI (2712)
XhoI (986)
EcoRI (953)
EcoRI (1675)
RGL for 1 (100.0%)
RGL for 3 (67.9%)
RGL rev 2 (100.0%)
RGL rev 4 (100.0%)
RGL-5-for (100.0%)
RGL-for-6 (100.0%)
RGL-rev-7 (100.0%)
pcDNA RGL C
7557 bp
6xHis
Amp(R)
Bsd(R)
V5 epitope
RGL C
SV40 pA
BGH pA
BGH reverse primer
CMV forward primer
T7 primer
V5 reverse primer
CMV promoter
SV40 early promoter
bla promoter
EM7 promoter
T7 promoter
f1 origin
pUC origin
XbaI (3405)
XcmI (2816)
XhoI (986)
EcoRI (953)
EcoRI (1779)
RGL for 1 (59.4%)
RGL for 3 (100.0%)
RGL rev 2 (100.0%)
RGL rev 4 (100.0%)
RGL-5-for (100.0%)
RGL-for-6 (100.0%)
RGL-rev-7 (100.0%)
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pcDNA RGL M
7446 bp
6xHis
Amp(R)
Bsd(R)
V 5 epitope
RGL M
S V 40 pA
BGH pA
BGH rev erse pr imer
CMV  forward pr imer
T7 primer
V 5 rev erse pr imer
CMV  promoter
S V 40 ear ly promoter
bla promoter
E M7 pr omoter
T7 promoter
f1 or igin
pUC or igin
XbaI (3294)
Xcm I (27 05)
Xho I (986)
Eco RI (953)
Eco RI (1668)
RGL for 1 (59.4%)
RGL for 3 (100.0%)
RGL rev 2 (100.0%)
RGL rev 4 (100.0%
RGL-5-for (100.0%
RGL-for-6 (100.0%)
RGL-rev-7 (100.0%
pcDNA Ciz F
7843 bp
6xHis
Amp(R)
Bsd(R)
V5 epitope
Ciz F
SV40 pA
BGH pA
BGH reverse primer
CMV forward primer
T7 primer
V5 reverse primer
CMV promoter
SV40 early promoter
bla promoter
EM7 promoter
T7 promoter
f1 origin
pUC origin
EcoRI (953)
XbaI (3691)
XhoI (986)
XcmI (1347)
XcmI (2954)
Ciz for 1 (100.0%)
Ciz for 3 (100.0%)
Ciz rev 2 (100.0%)
Ciz rev 4 (100.0%)
ciz-5-for (100.0%)
Ciz-6-rev (100.0%)
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pcDNA Ciz M (-84 bp)
7759 bp
6xHis
Amp(R)
Bsd(R)
V5 epitope
SV40 pA
BGH pA
BGH reverse primer
CMV forward primer
T7 primer
V5 reverse primer
CMV promoter
SV40 early promoter
bla promoter
EM7 promoter
T7 promoter
f1 origin
pUC origin
EcoRI (953)
XbaI (3607)
XhoI (986)
XcmI (1347)
XcmI (2870)
Ciz for 1 (100.0%)
Ciz for 3 (100.0%)
Ciz rev 2 (100.0%)
Ciz rev 4 (100.0%)
ciz-5-for (100.0%)
Ciz-6-rev (100.0%)
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13 Appendix IV: PCR on Ciz1 
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14 Appendix V: cDNA sequences 
14.1 Ciz1
       1 AACACGATTC CTCTGGCCAG GCCAAGGGGA GGGCGACACT GACAGGCGCC CCCCACCCAG  Exon 1 
      61 GGGCCGTGGC GAAGCAAGGG GCCGGCTGCT CAGAAAAGGA TAAGAAGTGG TTTCTCCTCC 
     121 CCTCTTCCCT TCCTCATCCT GCAGCCCGCG CCTCCCCCCT CGCCGCGCTG CGCACGGATG 
                           M  F  S   Q  Q  Q   Q  Q  Q   L  Q  Q  Q · 
     181 GCGGCGGGAG CCGCAGAG|CCACCATGTTCA GCCAGCAGCA GCAGCAGCAG CTCCAGCAAC  Exon 3 Ciz-for-1
 ·  Q  Q  Q   L  Q  Q   L  Q  Q  Q   Q  L  Q   Q  Q  Q   L  Q  Q  Q · 
     241 AGCAGCAGCA GCTCCAGCAG TTACAGCAGC AGCAGCTCCA GCAGCAGCAA TTGCAGCAGC 
 ·  Q  L  L   Q  L  Q   Q  L  L  Q   Q  S  P   P  Q  A   P  L  P  M · 
     301 AGCAGTTACT GCAGCTCCAG CAGCTGCTCC AGCAGTCCCC ACCACAGGCC CCGTTGCCCA 
 ·  A  V  S   R  G  L   P  P  Q  Q   P  Q  Q   P  L  L   N  L  Q  G · 
     361 TGGCTGTCAG CCG|GGGGCTCCCCCCGCAGC AGCCACAGCA GCCGCTTCTG AATCTCCAGG  Exon 4 
 ·  T  N  S   A  S  L   L  N  G  S   M  L  Q   R  A  L   L  L  Q  Q · 
     421 GCACCAACTC AGCCTCCCTC CTCAACGGCT CCATGCTGCA GAGAGCTTTG CTTTTACAGC 
 ·  L  Q  G   L  D  Q   F  A  M  P   P  A  T   Y  D  T   A  G  L  T · 
     481 AGTTGCAAG|GACTGGACCAG TTTGCAATGC CACCAGCCAC GTATGACACT GCCGGTCTCA  Exon 5 
 ·  M  P  T   A  T  L   G  N  L  R   G  Y  G   M  A  S   P  G  L  A · 
     541 CCATGCCCAC AGCAACACTG G|GTAACCTCCGAGGCTATGG CATGGCATCC CCAGGCCTCG  Exon 6 
 ·  A  P  S   L  T  P   P  Q  L  A   T  P  N   L  Q  Q   F  F  P  Q · 
     601 CAGCCCCCAG CCTCACACCC CCACAACTGG CCACTCCAAA TTTGCAACAG TTCTTTCCCC 
 ·  A  T  R   Q  S  L   L  G  P  P   P  V  G   V  P  M   N  P  S  Q · 
     661 AGGCCACTCG CCAGTCCTTG CTGGGACCTC CTCCTGTTGG GGTCCCCATG AACCCTTCCC 
 ·  F  N  L   S  G  R   N  P  Q  K   Q  A  R   T  S  S   S  T  T  P · 
     721 AGTTCAACCT TTCAGGACGG AACCCCCAGA AACAGGCCCG GACCTCCTCC TCTACCACCC 
 ·  N  R  K   D  S  S   S  Q  T  M   P  V  E   D  K  S   D  P  P  E · 
     781 CCAATCGAAA G|GATTCTTCTTCTCAGACAA TGCCTGTGGA AGACAAGTCA GACCCCCCAG  Exon 7 
 ·  G  S  E   E  A  A   E  P  R  M   D  T  P   E  D  Q   D  L  P  P · 
     841 AGGGGTCTGA GGAAGCCGCA GAGCCCCGGA TGGACACACC AGAAG|ACCAAGATTTACCGC  Exon 8 
 ·  C  P  E   D  I  A   K  E  K  R   T  P  A   P  E  P   E  P  C  E · 
     901 CCTGCCCAGA GGACATCGCC AAGGAAAAAC GCACTCCAGC ACCTGAGCCT GAGCCTTGTG 
 ·  A  S  E   L  P  A   K  R  L  R   S  S  E   E  P  T   E  K  E  P · 
     961 AGGCGTCCGA GCTGCCAGCA AAGAGATTGA GGAG|CTCAGAAGAGCCCACA GAGAAGGAAC  Exon 9 
 ·  P  G  Q   L  Q  V   K  A  Q  P   Q  A  R   M  T  V   P  K  Q  T · 
    1021 CTCCAGGGCA GTTACAGGTG AAGGCCCAGC CGCAGGCCCG GATGACAGTA CCGAAACAGA  Ciz-for-3
 ·  Q  T  P   D  L  L   P  E  A  L   E  A  Q   V  L  P   R  F  Q  P · 
    1081 CACAGACACC AGACCTGCTG CCTGAGGCCC TGGAAGCCCA AGTGCTGCCA CGATTCCAGC 
 ·  R  V  L   Q  V  Q   A  Q  V  Q   S  Q  T   Q  P  R   I  P  S  T · 
    1141 CACGGGTCCT GCAGGTCCAG GCCCAGGTGC AGTCACAGAC TCAGCCGCGG ATACCATCCA 
 ·  D  T  Q   V  Q  P   K  L  Q  K   Q  A  Q   T  Q  T   S  P  E  H · 
    1201 CAGACACCCA GGTGCAGCCA AAGCTGCAGA AGCAGGCGCA AACACAGACC TCTCCAGAGC 
 ·  L  V  L   Q  Q  K   Q  V  Q  P   Q  L  Q   Q  E  A   E  P  Q  K · 
    1261 ACTTAGTGCT GCAACAGAAG CAGGTGCAGC CACAGCTGCA GCAGGAGGCA GAGCCACAGA 
 ·  Q  V  Q   P  Q  V   Q  P  Q  A   H  S  Q   G  P  R   Q  V  Q  L · 
    1321 AGCAGGTGCA GCCACAGGTA CAGCCACAGG CACATTCACA GGGCCCAAGG CAGGTGCAGC  ** 
 ·  Q  Q  E   A  E  P   L  K  Q  V   Q  P  Q   V  Q  P   Q  A  H  S · 
    1381 TGCAGCAGGA GGCAGAGCCG CTGAAGCAGG TGCAGCCACA GGTGCAGCCC CAGGCACATT  ***  
 ·  Q  P  P   R  Q  V   Q  L  Q  L   Q  K  Q   V  Q  T   Q  T  Y  P · 
    1441 CACAGCCCCC AAGGCAGGTG CAGCTGCAGC TGCAGAAGCA GGTCCAGACA CAGACATATC 
 ·  Q  V  H   T  Q  A   Q  P  S  V   Q  P  Q   E  H  P   P  A  Q  V · 
    1501 CACAGGTCCA CACACAGGCA CAGCCAAGCG TCCAGCCACA GGAGCATCCT CCAGCGCAGG 
 ·  S  V  Q   P  P  E   Q  T  H  E   Q  P  H   T  Q  P   Q  V  S  L · 
    1561 TGTCAGTACA GCCACCAGAG CAGACCCATG AGCAGCCTCA CACCCAGCCG CAGGTGTCGT 
 ·  L  A  P   E  Q  T   P  V  V  V   H  V  C   G  L  E   M  P  P  D · 
    1621 TGCTGGCTCC AGAGCAAACA CCAGTTGTGG TTCATGTCTG CGGGCTGGAG ATGCCACCTG  Ciz-rev-4
 ·  A  V  E   A  G  G   G  M  E  K   T  L  P   E  P  V   G  T  Q  V · 
    1681 ATGCAGTAGA AGCTGGTGGA G|GCATGGAAAAGACCTTGCC AGAGCCTGTG GGCACCCAAG   Exon 10 
 ·  S  M  E   E  I  Q   N  E  S  A   C  G  L   D  V  G   E  C  E  N · 
    1741 TCAGCATGGA AGAGATTCAG AATGAGTCGG CCTGTGGCCT AGATGTGGGA GAATGTGAAA 
 ·  R  A  R   E  M  P   G  V  W  G   A  G  G   S  L  K   V  T  I  L · 
    1801 ACAGAGCGAG AGAGATGCCA GGG|GTATGGGGCGCCGGGGG CTCCCTGAAG GTCACCATTC   Exon 11 
 ·  Q  S  S   D  S  R   A  F  S  T   V  P  L   T  P  V   P  R  P  S · 
    1861 TGCAGAGCAG TGACAGCCGG GCCTTTAGCA CTGTACCCCT GACACCTGTC CCCCGCCCCA 
 ·  D  S  V   S  S  T   P  A  A  T   S  T  P   S  K  Q   A  L  Q  F · 
    1921 GTGACTCCGT CTCCTCCACC CCTGCGGCTA CCAGCACTCC CTCTAAGCAG GCCCTCCAGT 
 ·  F  C  Y   I  C  K   A  S  C  S   S  Q  Q   E  F  Q   D  H  M  S · 
    1981 TCTTCTGCTA CATCTGCAAG GCCAGCTGCT CCAGCCAGCA G|GAGTTCCAGGACCACATGT   Exon 12 
 ·  E  P  Q   H  Q  Q   R  L  G  E   I  Q  H   M  S  Q   A  C  L  L · 
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    2041 CGGAGCCTCA GCACCAGCAG CGGCTAGGGG AGATCCAGCA CATGAGCCAA GCCTGCCTCC 
 ·  S  L  L   P  V  P   R  D  V  L   E  T  E   D  E  E   P  P  P  R · 
    2101 TGTCCCTGCT GCCCGTGCCC CGGGACGTCC TGGAGACAGA GGATGA|GGAGCCTCCACCAA   Exon 13 
 ·  R  W  C   N  T  C   Q  L  Y  Y   M  G  D   L  I  Q   H  R  R  T · 
    2161 GGCGCTGGTG CAACACCTGC CAGCTCTACT ACATGGGGGA CCTGATCCAA CACCGCAGGA 
 ·  Q  D  H   K  I  A   K  Q  S  L   R  P  F   C  T  V   C  N  R  Y · 
    2221 CACAGGACCA CAAG|ATTGCCAAACAATCCT TGCGACCCTT CTGCACCGTT TGCAACCGCT   Exon 14 
 ·  F  K  T   P  R  K   F  V  E  H   V  K  S   Q  G  H   K  D  K  A · 
    2281 ACTTCAAAAC CCCTCGCAAG TTTGTGGAGC ACGTGAAGTC CCAGGGGCAT AAGGACAAAG 
 ·  K  E  L   K  S  L   E  K  E  I   A  G  Q   D  E  D   H  F  I  T · 
    2341 CCAAGGAG|CTGAAGTCGCTT GAGAAAGAAA TTGCTGGCCA AGATGAGGAC CACTTCATTA   Exon 15 
 ·  V  D  A   V  G  C   F  E  G  D   E  E  E   E  E  D   D  E  D  E · 
    2401 CAGTGGACGC TGTGGGTTGC TTCGAGGGTG ATGAAGAAGA GGAAGAGGAT GATGAGGATG 
 ·  E  E  I   E  V  E   E  E  L  C   K  Q  V   R  S  R   D  I  S  R · 
    2461 AAGAAGAGAT CGAGGTTGAG GAGGAACTCT GCAAGCAG|GTGAGGTCCAGA GATATATCCA   Exon 16 
 ·  E  E  W   K  G  S   E  T  Y  S   P  N  T   A  Y  G   V  D  F  L · 
    2521 GAGAGGAGTG GAAGGGCTCG GAGACCTACA GCCCCAATAC TGCATATG|GTGTGGACTTCC   Exon 17 
 ·  V  P  V   M  G  Y   I  C  R  I   C  H  K   F  Y  H   S  N  S  G · 
    2581 TGGTGCCCGT GATGGGCTAT ATCTGCCGCA TCTGCCACAA GTTCTATCAC AGCAACTCAG 
 ·  A  Q  L   S  H  C   K  S  L  G   H  F  E   N  L  Q   K  Y  K  A · 
    2641 GGGCACAGCT CTCCCACTGC AAGTCCCTGG GCCACTTTGA GAACCTGCAG|AAATACAAGG   Exon 18 
 ·  A  K  N   P  S  P   T  T  R  P   V  S  R   R  C  A   I  N  A  R · 
    2701 CGGCCAAGAA CCCCAGCCCC ACCACCCGAC CTGTGAGCCG CCGGTGCGCA ATCAACGCCC 
 ·  N  A  L   T  A  L   F  T  S  S   G  R  P   P  S  Q   P  N  T  Q · 
    2761 GGAACGCTTT GACAGCCCTG TTCACCTCCA GCGGCCGCCC ACCCTCCCAG CCCAACACCC 
 ·  D  K  T   P  S  K   V  T  A  R   P  S  Q   P  P  L   P  R  R  S · 
    2821 AGGACAAAAC ACCCAGCAAG GTGACGGCTC GACCCTCCCA GCCCCCACTA CCTCGGCGCT  Ciz-rev-2
 ·  T  R  L   K  T  * 
    2881 CAACCCGCCT CAAAACCTGA TAGAGGGACC TCCCTGTCCC TGGCCTGCCT GGGTCCAGAT 
    2941 CTGCTAATGC TTTTTAGGAG TCTGCCTGGA AACTTTGACA TGGTTCATGT TTTTACTCAA 
    3001 AATCCAATAA AACAAGGTAG TTTGGCTGTG CA 
Full length transcript (NM_012127) 
** Yellow and green region of 168 bp lacking. (AK023978) 
*** green region of 84 bp lacking. (BC004.119) 
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14.2 RGL1 
RGL A has exon 3 as first exon (AF186779): 
       1 GTGGCCCGAG TCGCGCGCAC CGGCGGCGGC GGGGGCAGCG CGGCGCGTGT CTGTGCGCTG   Exon 3 
      61 CGGTCGCTCG GGACCGGGAC CGGGGCGAGG CGCCGCGGGG CTGAGCCCAG CAGACATTGC 
                                                                 M · 
     121 GTTGGCCTCC GAGCAGGGCG CATCATGCAG CGTTCGCGCA CCGGAGAGAA AACTGAGAAT   RGL-for-1
 · K  L  L   W  Q  A  K   M   
     181 GAAATTGCTT TGGCAAGCTA AAATG| 
RGL C and M has exon 1 and 2 as first exons (AF186780): 
       1 CTGCGGTCCA GTCTAGGGGG TCTCAGATTG GCGGGGATGG GCAGCAGCGG CAGGTGGCCT   Exon 1 
      61 TGGCTTTTGC TGCAGCCGTC AACGACCTAT CATCGGGGTC CTGCGTAAGG TCCGGCTGGC 
     121 TGGGACTTGG CTGTGGGTGG GATGGACTGG CTGCCGGACC GAGTGCCCTG CAGTTGGTAG 
     181 GAGTATGAGG CAGAGTGATG CACACCCGGG CGCCCAGCAT CGTTCTAATT GCCGGAGACA 
     241 TTGCCTCAGA CTGTGCGCTG CTAGAGGCTG CGTTCCTGAG CAGGAAGCCC GTTTCCTGGG 
     301 ATTGGAACTA CCCTTCTTGG CCAGCGGGAA GTCCCCAAGG ACGGAGTCGA AAGGTCAAAT 
     361 CTTATCTGTC AGTGCTGTGT GACAGCATCG CAACGGGATC TGCAGAACCTGAACTCG|ATC  Exon 2 
                                 M   E  V  K   P  V  G   E  P  T  Q · 
     421 CGTAATGCCT CCTGCCTGCC TCTTTCAAGA TGGAGGTGAA ACCTGTGGGA GAACCTACTC  RGL-for-3
 ·  E  V  S   K  F  K   L  S  T  K   V  E  S   T  G  H   W  L  V  E · 
     481 AAGAGGTGTC TAAATTCAAA CTTTCCACCA AGGTAGAAAG CACGGGACAC TGGCTGGTGG 
 ·  D  H  V   R  I  W   E  V  L  K   T  E  E   S  S  I   Q  D  W  G · 
     541 AAGATCATGT TCGAATATGG GAAGTTTTAA AGACAGAGGA G|AGCTCGATTCAGGACTGGG   Exon 4 ** 
 ·  E  E  V   E  E  G   A  V  Y  H   V  T  L   K  R  V   Q  I  Q  Q · 
     601 GTGAAGAGGT AGAGGAAGGA GCTGTTTACC ATGTCACCCT CAAAAGAGTC CAGATTCAAC 
 ·  A  A  N   K  G  A   R  W  L  G   V  E  G   D  Q  L   P  P  G  H · 
     661 AGGCTGCCAA TAAAGGAGCA AGATGGCTAG GG|GTTGAAGGGGACCAGCTG CCTCCAGGAC   Exon 5 
 ·  T  V  S   Q  Y  E   T  C  K  I   R  T  I   K  A  G   T  L  E  K · 
     721 ACACAGTCAG TCAATATGAA ACCTGTAAGA TCAGGACCAT AAAAGCTGGC ACCTTGGAGA 
 ·  L  V  E   N  L  L   T  A  F  G   D  N  D   F  T  Y   I  S  I  F · 
     781 AGCTTGTGGA GAACCTGCTG ACAGCTTTTG GGGACAATGA CTTTACCTAT ATCAGCATCT   RGL-rev-4
 ·  L  S  T   Y  R  G   F  A  S  T   K  E  V   L  E  L   L  L  D  R · 
     841 TTCTTTCAAC GTACAGAGGC TTTGCCTCCA CTAAAGAAGT GCTGGAACTA CTGCTGGACA 
 ·  Y  G  N   L  T  S   P  N  C  E   E  D  G   S  Q  S   S  S  E  S · 
     901 G|GTATGGAAACCTGACAAGC CCAAACTGTG AAGAAGATGG AAGCCAAAGT TCATCAGAGT   Exon 6 
 ·  K  M  V   I  R  N   A  I  A  S   I  L  R   A  W  L   D  Q  C  A · 
     961 CCAAAATGGT GATCAGGAA|TGCAATCGCTT CCATACTAAG GGCCTGGCTT GACCAGTGTG   Exon 7 
 ·  E  D  F   R  E  P   P  H  F  P   C  L  Q   K  L  L   D  Y  L  T · 
    1021 CAGAAGACTT CCGAGAGCCC CCTCACTTCC CTTGCTTACA GAAACTGCTG GATTATCTCA 
 ·  R  M  M   P  G  S   D  P  E  R   R  A  Q   N  L  L   E  Q  F  Q · 
    1081 CACGGATGAT GCCGGGCTCT GACCCAGAAA GAAGAGCACA AAATCTTCTT GAGCAGTTTC 
 ·  K  Q  E   V  E  T   D  N  G  L   P  N  T   I  S  F   S  L  E  E · 
    1141 AGAAGCAAGA AGTGGAAACT GACA|ATGGGCTTCCCAACAC GATCTCCTTC AGCCTGGAAG   Exon 8 
 ·  E  E  E   L  E  G   G  E  S  A   E  F  T   C  F  S   E  D  L  V · 
    1201 AGGAAGAGGA ACTGGAGGGT GGAGAGTCAG CAGAATTCAC GTGCTTCTCA GAAGATCTCG 
 ·  A  E  Q   L  T  Y   M  D  A  Q   L  F  K   K  V  V   P  H  H  C · 
    1261 TGGCAGAGCA GCTGACCTAC ATGGATGCA|CAACTCTTCAA GAAAGTAGTG CCTCACCACT   Exon 9 
 ·  L  G  C   I  W  S   R  R  D  K   K  E  N   K  H  L   A  P  T  I · 
    1321 GCCTGGGCTG CATTTGGTCT CGAAGGGATA AGAAGGAAAA CAAACATTTG GCTCCTACGA 
 ·  R  A  T   I  S  Q   F  N  T  L   T  K  C   V  V  S   T  I  L  G · 
    1381 TCCGTGCCAC CATCTCTCAG TTTAATACCC TCACCAAATG TGTTGTCAGC ACCATCCTGG 
 ·  G  K  E   L  K  T   Q  Q  R  A   K  I  I   E  K  W   I  N  I  A · 
    1441 GGGGCAAAGA ACTCAAAACT CAGCAGAGAG CCAAAATCAT TGAGAAGTGG ATCAACATCG 
 ·  H  E  C   R  L  L   K  N  F  S   S  L  R   A  I  V   S  A  L  Q · 
    1501 CTCAT|GAATGTAGACTCCTG AAGAATTTTT CCTCCTTGAG GGCCATCGTT TCGGCACTGC   Exon 10 
 ·  S  N  S   I  Y  R   L  K  K  T   W  A  A   V  P  R   D  R  M  L · 
    1561 AGTCTAATTC CATCTATCGG TTAAAAAAGA CTTGGGCTGC CGTCCCAAG|GGACCGAATGC   Exon 11 
 ·  M  F  E   E  L  S   D  I  F  S   D  H  N   N  H  L   T  S  R  E · 
    1621 TGATGTTTGA AGAACTTTCA GATATCTTCT CAGACCATAA TAACCATTTG ACCAGCCGAG 
 ·  L  L  M   K  E  G   T  S  K  F   A  N  L   D  S  S   V  K  E  N · 
    1681 AACTACTGAT GAAG|GAAGGAACCTCAAAAT TTGCAAACCT GGACAGCAGT GTGAAAGAAA   Exon 12 
 ·  Q  K  R   T  Q  R   R  L  Q  L   Q  K  D   M  G  V   M  Q  G  T · 
    1741 ACCAGAAGCG TACCCAGAGG CGGCTGCAGC TCCAGAAGGA CATG|GGTGTGATGCAGGGAA   Exon 13 
 ·  V  P  Y   L  G  T   F  L  T  D   L  T  M   L  D  T   A  L  Q  D · 
    1801 CTGTGCCCTA CCTGGGCACC TTCCTGACTG ACCTGACCAT GCTTGACACT GCCCTTCAGG 
 ·  Y  I  E   G  G  L   I  N  F  E   K  R  R   R  E  F   E  V  I  A · 
    1861 ACTACATCGA G|GGTGGACTGATAAACTTTG AGAAAAGGAG AAGG|GAATTTGAAGTGATTG  Exon 14,15 
 ·  Q  I  K   L  L  Q   S  A  C  N   S  Y  C   M  T  P   D  Q  K  F · 
    1921 CCCAGATAAA GCTCTTACAG TCTGCCTGCA ACAGCTATTG CATGACCCCA GACCAAAAGT 
 ·  I  Q  W   F  Q  R   Q  Q  L  L   T  E  E   E  S  Y   A  L  S  C · 
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    1981 TCATCCAGTG GTTCCAGAGG CAGCAGCTCC TGACAGAGGA GGAGAG|CTATGCCCTGTCAT   Exon 16 
 ·  E  I  E   A  A  A   D  A  S  T   T  S  P   K  P  R   K  S  M  V · 
    2041 GTGAGATTGA AGCAGCTGCT GACGCCAGCA CCACCTCGCC CAAGCCTCGG AAGAGCATGG 
 ·  K  R  L   S  L  L   F  L  G  S   D  M  I   T  S  P   T  P  T  K · 
    2101 TGAAGAGACT CAGCCT|ACTGTTTCTAGGGT CTGACATGAT CACCAGTCCC ACTCCCACCA   Exon 17 
 ·  E  Q  P   K  S  T   A  S  G  S   S  G  E   S  M  D   S  V  S  V · 
    2161 AAGAGCAGCC CAAGTCCACT GCCAGCGGGA GCTCTGGTGA AAGCATGGAC TCTGTCAGCG 
 ·  S  S  C   E  S  N   H  S  E  A   E  E  G   S  I  T   P  M  D  T · 
    2221 TGTCATCCTG CGAGTCGAAC CACTCAGAGG CTGAGGAGGG CTCCATTACT CCCATGGACA 
 ·  P  D  E   P  Q  K   K  L  S  E   S  S  S   S  C  S   S  I  H  S · 
    2281 CCCCTGATGA GCCTCAAAAA AAG|CTCTCTGAGTCCTCCTC ATCCTGTTCT TCTATCCATT   Exon 18 
 ·  M  D  T   N  S  S   G  M  S  S   L  I  N   P  L  S   S  P  P  S · 
    2341 CCATGGACAC AAATTCCTCA GGGATGTCTT CCTTAATCAA CCCCCTCTCC TCCCCTCCGT 
 ·  C  N  N   N  P  K   I  H  K  R   S  V  S   V  T  S   I  T  S  T · 
    2401 CCTGCAACAA CAACCCCAAA ATCCACAAGC GCTCTGTCTC GGTGACGTCC ATTACCTCGA 
 ·  V  L  P   P  V  Y   N  Q  Q  N   E  D  T   C  I  I   R  I  S  V · 
    2461 CTGTGCTGCC TCCTGTTTAC AACCAACAGA ATGAAGACAC CTGCATAATC CGCATCAGTG 
 ·  E  D  N   N  G  N   M  Y  K  S   I  M  L   T  S  Q   D  K  T  P · 
    2521 TGGAAGACAA TAACGGCAAC ATGTACAAGA GCATCATG|TTGACGAGCCAG GATAAAACCC   Exon 19 
 ·  A  V  I   Q  R  A   M  L  K  H   N  L  D   S  D  P   A  E  E  Y · 
    2581 CCGCTGTGAT CCAGAGAGCC ATGCTGAAGC ACAATCTGGA CTCAGACCCC GCCGAGGAGT 
 ·  E  L  V   Q  V  I   S  E  D  K   E  L  V   I  P  D   S  A  N  V · 
    2641 ACGAGCTGGT GCAGGTCATC TCGGAGGACA AAG|AACTTGTGATTCCAGAC TCAGCAAATG   Exon 20 
 ·  F  Y  A   M  N  S   Q  V  N  F   D  F  I   L  R  K   K  N  S  M · 
    2701 TCTTTTATGC CATGAACAGC CAAGTGAACT TTGACTTCAT TTTGCGCAAA AAGAACTCCA 
 ·  E  E  Q   V  K  L   R  S  R  T   S  L  T   L  P  R   T  A  K  R · 
    2761 TGGAAGAACA AGTGAAACTG CGTAGCCGGA CCAGCTTGAC GTTGCCCAGG ACAGCTAAAC 
 ·  G  C  W   S  Y  R   H  S  K  I   T  L  * 
    2821 GGGGCTGCTG GAGTTACAGA CACAGCAAAA TCACCCTCTG AAGGGAGGGM CCAGTGGCCC  RGL-rev-2
    2881 CTTGTTTGCC AAAGGCAGAG TGGGGCTGAG AAACAGGCTG CGGTGATTGC AATTACCATC 
    2941 CGGTGTTCGA GGATCATTGG TGAAGTCAGC AGATATTTAT TGAGTTCCTG TGGTGTGCAA 
    3001 AGCATTATGA TAGGCACCGT GGGGAAACTG GAAATGAATT TGACATGAAA AGGATGAACG 
    3061 ATTCACTGAT TCTCTTTGAC TCATTTGAGA CTAAAATGCA GAATTACCAA CATTTAAAAC 
    3121 ATATATATGC ACATGTATTT GGTATGCATG TGTATCTATA TAAAAATATA TAAGAGGGAC 
    3181 TTTATGGGAT AGTATGGACT ATGGAAAAAC AAATTTGCAC AATGGCCTGG GAAGTTGAGG 
    3241 TCACTTTTTA CAGGGAAATA GAAGAAACTG AGAACCTAGT CTCGTATATT CTGAGTAAAT 
    3301 GGAATCAGTC CTGGGAATAG AGAGTGTCCT TTGTGCCAGT ATTACAAGAA GCCCAAACTT 
    3361 TATTTTTATA AAGGGAGAGG ATGACTTTCT CAATCAAGTG CCACCAGATA AAAACAACTG 
    3421 CAGAGGCTGG AACTGCCACA GGCTGTATGA AAGGCCACTT TGGAAAGGGT TTGGATGAGC 
    3481 TGGTGGCCTT CAACCTCTGC CTGCATCTGC CACTTTCTGC TACCCTAGGG AGGCCAGGAG 
    3541 GAGCTTCGGA GGACCATCGC CCCACTGGTC TAGCCATCAT GACACCTCTG GAGGTGTCAA 
    3601 GCTCCTGAAA CAAGCTCATT TCAGTTTCTG GCAACCCCGT GTATTTCCGT TTTCCCCCTA 
    3661 AAGAACATAT CATAATCATT GCACAAATAA CCATGTTCTT TGGTAATGAA GCCAGAAAAG 
    3721 AAAGCGCAAA AGAATGGTGA CTCATTTGGA CTCTTATCTG TCTTGGAATG TCACTGCTTC 
    3781 ATTGCCTTCT CTGATTGCCT TTTGCATGTA AAACTATGTG TCTGGAGTCT TTTGCCATCT 
    3841 GGATCTTAGT ACCTCTTTAT TATGTGCAAT TTATTCCTCA GGTGTGGAAA TTTCTACTGC 
    3901 AATTGACTGA CGTKTGATTA TTTTGAGCTT GTGAAAGATT TCTGAACAGT GATTGTCCCG 
    3961 TTAATAGCCC CTCAGAAGAT GTTCCCTGCT GATAACAGCA TCCTATTTTA CTTACTTTTA 
    4021 TAGCATTACT GTGCCTAGTC GTGGGGAAAG AGATGGGGCT GTATAGATTA TCTGAATCAT 
    4081 TTGTCTAAGA GGTACATTCT TCCAGATGGA ATCAATAACT TTTTTTTTTC CAGGTTCCCG 
    4141 TGCTTGCTAT CACAGTATCA TTGTTAAGTG ACACTTTTGT CTCTCATAAC ACCATCACAC 
    4201 TCTTCCTTCC AAGTCTGAGC TGTGCTGGGG TTTGAACTAA AAGCCATATG TGGAATATTG 
    4261 ACATGTGTAA GAAGCACTTT CAGAATGTTG TCCTTTTTAA GAAATGATTC TCAAAATACC 
    4321 AGTTTTTATT CCAAAAATTT AGAGAACAAA CCCGGAATAT GAAGTGCAGA TTGTAACATG 
    4381 GAGCTATTTT TTTTTCCTAA TCCCATAATA CAGCTCCTAA AAGTTGTGTG GGATTTGCGT 
    4441 TGCATAAATA GCCATGTGAA TTCCACAAGA AGCACCAGGG AAAGTTTAGA GATTTGCGGC 
    4501 AATGGACCGA AGAACGGGCC AGGAAGTCCT CCAATTTCCT TTGGTCTTTC CAGGAGATTG 
    4561 GACTACACAT TGTAAAGACT GACTGGGTTT CAACTAGTCA AAAAGCACTT TCTTCTGTTT 
    4621 TCAATCCCTG TTCGATTTGT GCTTCTGTGC TTGTAGGAGA GATGGCCAGG GTGGCAGCCC 
    4681 TCATGCAGGT TGAAGTATAT GTAGCCTCAG CCTGATATTC TTGGTGCGAA GGTAAAAAAA 
    4741 AAAAAAATAA ATAAAACCAT TGGCCTGGTT GAGGGCGTGA CCACCAAGAC ATATATGTTG 
    4801 TGCCCGTGTT CATCCTGTGT ATTTATACTG TATATGTAGA GTCTAGATTT ATATACTGCA 
    4861 ATGTAAAATA TATATATATT TACCTTTTTT AAAGACAATG GAAATTCCAA GTAGCTAAAA 
    4921 CTTAGCTTCA TTTATTTAAT GCCACTTTAA ATGTCTTAAA TTTGTTTCCT GGTGGACAGC 
    4981 CGGGTAATGC TTTTAGCTGC TCGCATGCTT GTCTTTCTGC ATCTCCATCA TCTGTTTACC 
    5041 TTTTGGTTAA ACTAATAAAC TAGTTTGGGA CTTGGCTGGC ATGTGCTGCC AGACCCAAAG 
    5101 GGAAAAAAAA A 
** RGL M is lacking exon 4 of 111 bp (predicted CR857838; Pongo pygmaeus).  
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14.3 Ephrin A3 
       1 GGAGCTGGGA AGCGGAGAAG CCGGGAGCGC GGGGCTCAGT CGGGGGGCGG CGGCGGCGGC   Exon 1 
             M  A  A  A   P  L  L   L  L  L   L  L  V  P   V  P  L · 
      61 GGCTCCGGGG ATGGCGGCGG CTCCGCTGCT GCTGCTGCTG CTGCTCGTGC CCGTGCCGCT 
 · L  P  L   L  A  Q  G   P  G  G   A  L  G   N  R  H  A   V  Y  W · 
     121 GCTGCCGCTG CTGGCCCAAG GGCCCGGAGG GGCGCTGGGA AACCGGCATG CGGTGTACTG 
 · N  S  S   N  Q  H  L   R  R  E   G  Y  T   V  Q  V  N   V  N  D · 
     181 GAACAGCTCC AACCAGCA|CCTGCGGCGAGA GGGCTACACC GTGCAGGTGA ACGTGAACGA   Exon 2 
 · Y  L  D   I  Y  C  P   H  Y  N   S  S  G   V  G  P  G   A  G  P · 
     241 CTATCTGGAT ATTTACTGCC CGCACTACAA CAGCTCGGGG GTGGGCCCCG GGGCGGGACC 
 · G  P  G   G  G  A  E   Q  Y  V   L  Y  M   V  S  R  N   G  Y  R · 
     301 GGGGCCCGGA GGCGGGGCAG AGCAGTACGT GCTGTACATG GTGAGCCGCA ACGGCTACCG 
 · T  C  N   A  S  Q  G   F  K  R   W  E  C   N  R  P  H   A  P  H · 
     361 CACCTGCAAC GCCAGCCAGG GCTTCAAGCG CTGGGAGTGC AACCGGCCGC ACGCCCCGCA 
 · S  P  I   K  F  S  E   K  F  Q   R  Y  S   A  F  S  L   G  Y  E · 
     421 CAGCCCCATC AAGTTCTCGG AGAAGTTCCA GCGCTACAGC GCCTTCTCTC TGGGCTACGA 
 · F  H  A   G  H  E  Y   Y  Y  I   S  T  P   T  H  N  L   H  W  K · 
     481 GTTCCACGCC GGCCACGAGT ACTACTACAT CT|CCACGCCCACTCACAACC TGCACTGGAA   Exon 3 
 · C  L  R   M  K  V  F   V  C  C   A  S  T   S  H  S  G   E  K  P · Eph-for-3
     541 GTGTCTGAGG ATGAAGGTGT TCGTCTGCTG CGCCTCCA|CATCGCACTCCG GGGAGAAGCC ** Exon 4 
 · V  P  T   L  P  Q  F   T  M  G   P  N  V   K  I  N  V   L  E  D · 
     601 GGTCCCCACT CTCCCCCAGT TCACCATGGG CCCCAATGTG AAGATCAACGTGCTGG|AAGA   Exon 5 
 · F  E  G   E  N  P  Q   V  P  K   L  E  K   S  I  S  G   T  S  P · 
     661 CTTTGAGGGA GAGAACCCTC AGGTGCCCAA GCTTGAGAAG AGCATCAGCG GGACCAGCCC 
 · K  R  E   H  L  P  L   A  V  G   I  A  F   F  L  M  T   F  L  A · 
     721 CAAACGGGAA CACCTGCCCC TGGCCGTGGG CATCGCCTTC TTCCTCATGA CGTTCTTGGC   Eph-rev-2
 · S  * 
     781 CTCCTAGCTC TGCCCCCTCC CCTGGGGGGG GAGAGATGGG GCGGGGCTTG GAAGGAGCAG 
     841 GGAGCCTTTG GCCTCTCCAA GGGAAGCCTA GTGGGCCTAG ACCCCTCCTC CCATGGCTAG 
     901 AAGTGGGGCC TGCACCATAC ATCTGTGTCC GCCCCCTCTA CCCCTTCCCC CCACGTAGGG 
     961 CACTGTAGTG GACCAAGCAC GGGGACAGCC ATGGGTCCCG GGCGGCCTTG TGGCTCTGGT 
    1021 AATGTTTGGT ACCAAACTTG GGGGCCAAAA AGGGCAGTGC TCAGGACTCC CTGGCCCCTG 
    1081 GTACCTTTCC CTGACTCCTG GTGCCCTCTC CCTTTGTCCC CCCAGAGAGA CATATGCCCC 
    1141 CAGAGAGAGC AAATCGAAGC GTGGGAGGCA CCCCCATTGC TCTCCTCCAG GGGCAGAACA 
    1201 TGGGGAGGGG ACTAGATGGG CAAGGGGCAG CACTGCCTGC TGCTTCCTTC CCCTGTTTAC 
    1261 AGCAATAAGC ACGTCCTCCT CCCCCACTCC CACTTCCAGG ATTGTGGTTT GGATTGAAAC 
    1321 CAAGTTTACA AGTAGACACC CCTGGGGGGG CGGGCAGTGG ACAAGGATGG CAAGGGGTGG 
    1381 GCATTGGGGT GCCAGGCAGG CATGTACAGA CTCTATATCT CTATATATAA TGTACAGACA 
    1441 GACAGAGTCC CTTCCCTCTT TAACCCCCTG ACCTTTCTTG ACTTCCCCTT CAGCTTCAGA 
    1501 CCCCTTCCCC ACCAGGCTAG GCCCCCCACA CCTGGGGGAC CCCCTGGCCC CTCTTTTGTC 
    1561 TTCTGTGAAG ACAGGACCTA TGCAACGCAC AGACACTTTT GGAGACCGTA AAACAACAAC 
    1621 GCCCCCTCCC TTCCAGCCCT GAGCCGGGAA CCATCTCCCA GGACCTTGCC CTGCTCACCC 
    1681 TATGTGGTCC CACCTATCCT CCTGGGCCTT TTTCAAGTGC TTTGGCTGTG ACTTTCATAC 
    1741 TCTGCTCTTA GTCTAAAAAA AATAAACTGG AGATAAAAAT AAAAAAAAAA AAAAAAAA 
Full length (NM_004952) 
** exon 4 is lacking in Ephrin L (predicted XM_001072619; Rattus norvegicus).  
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15 Appendix VI: Alignment of RalGDS family proteins 
                 1                                                         60 
   RalGDS    (1) MVQRMWAEAAGPAGGAEPLFPGSRRSRSVWDAVRLEVGVPDSCPVVLHSFTQLDPDLPRP
    RGL 1    (1) ---------------------------------------------VAAARVTMKLLWQAK
    RGL 2    (1) ---------------------------MLPRPLRLLLDTSPPGGVVLSSFRSRDPEEGGG
    RGL 3    (1) --------------------------------------------------MERTAGKELA
                 61                                                       120 
   RalGDS   (61) ESSTQEIGEELINGVIYSISLRKVQLHHGGNKGQRWLGYE-----NESALNLYETCKVRT
    RGL 1   (16) MSSIQDWGEEVEEGAVYHVTLKRVQIQQAANKGARWLGVEGDQLPPGHTVSQYETCKIRT
    RGL 2   (34) PGGLVVGGGQEEE--EEEEEEAPVSVWDEEEDGAVFTVTSRQYRPLDPLVPMPPPRSSRR
    RGL 3   (11) LAPLQDWGEETEDGAVYSVSLRRQRSQR--RSPAEGPGGSQAPSPIANTFLHYRTSKVRV
                 121                                                      180 
   RalGDS  (116) VKAGTLEKLVEHLVPA-FQGSDLSYVTIFLCTYRAFTTTQQVLDLLFKRYGCILPYSDED
    RGL 1   (76) IKAGTLEKLVENLLTA-FGDNDFTYISIFLSTYRGFASTKEVLELLLDRYGNLTSPNCEE
    RGL 2   (92) LRAGTLEALVRHLLDTRTSGTDVSFMSAFLATHRAFTSTPALLGLMADRLEALESHPTDE
    RGL 3   (69) LRAARLERLVGELVFG-DREQDPSFMPAFLATYRTFVPTACLLGFLLPPMPPPPPPGVEI
                 181                                                      240 
   RalGDS  (175) GGPQ------DQLKNAISSILGTWLDQYSEDFCQPPDFPCLKQLVAYVQLNMPGSDLERR
    RGL 1  (135) DGSQSSSESKMVIRNAIASILRAWLDQCAEDFREPPHFPCLQKLLDYLTRMMPGSDPERR
    RGL 2  (152) LERT---------TEVAISVLSTWLASHPEDFG-SEAKGQLDRLESFLLQTGYAAGKGVG
    RGL 3  (128) KKTAVQDLSFNKNLRAVVSVLGSWLQDHPQDFRDPPVHSDLGSVRTFLGWAAPGSAEAQK
                 241                                                      300 
   RalGDS  (229) --AHLLLAQLEHSEPIEAEPEALSPVPALKPTPELELALTPARAPSPVPAPAPEPEPAPT
    RGL 1  (195) --AQNLLEQFQKQE-----------------------VETDNGLPNTISFSLEEEE----
    RGL 2  (202) GGSADLIRNLRSRVDP-----------------------QAPDLPKPLALPGDPPA----
    RGL 3  (188) --AEKLLEDFLEEAEREQEEEPPQVWTGPP-------RVAQTSDPDSSEACAEEEE----
                 301                                                      360 
   RalGDS  (287) PAPGSELEVAPAPAPELQQAPEPAVGLESAPAPALELEPAPEQDPAPSQTLELEPAPAPV
    RGL 1  (226) ---------------------------------------------------ELE---G--
    RGL 2  (235) ------------------------------------------------------------ 
    RGL 3  (235) ---------------------------------------------------GLMP-----
                 361                                                      420 
   RalGDS  (347) PSLQPSWPSPVVAENGLSEEKPHLLVFPPDLVAEQFTLMDAELFKKVVPYHCLGSIWSQR
    RGL 1  (230) ----G--------------ESAEFTCFSEDLVAEQLTYMDAQLFKKVVPHHCLGCIWSRR
    RGL 2  (235) -------------------DPTDVLVFLADHLAEQLTLLDAELFLNLIPSQCLGGLWGHR
    RGL 3  (239) -------------------QGPQLLDFSVDEVAEQLTLIDLELFSKVRLYECLGSVWSQR
                 421                                                      480 
   RalGDS  (407) DKKGKEHLAPTIRATVTQFNSVANCVITTCLGNRS------------TKAPDRARVVEHW
    RGL 1  (272) DKKENKHLAPTIRATISQFNTLTKCVVSTILGGKE------------LKTQQRAKIIEKW
    RGL 2  (276) DRPGHSHLCPSVRATVTQFNKVAGAVVSSVLGATSTGEGPGEVTIRPLRPPQRARLLEKW
    RGL 3  (280) DRPGAAGASPTVRATVAQFNTVTGCVLGSVLGAPG------------LAAPQRAQRLEKW
                 481                                                      540 
   RalGDS  (455) IEVARECRILKNFSSLYAILSALQSNSIHRLKKTWEDVSRDSFRIFQKLSEIFSDENNYS
    RGL 1  (320) INIAHECRLLKNFSSLRAIVSALQSNSIYRLKKTWAAVPRDRMLMFEELSDIFSDHNNHL
    RGL 2  (336) IRVAEECRLLRNFSSVYAVVSALQSSPIHRLRAAWGEATRDSLRVFSSLCQIFSEEDNYS
    RGL 3  (328) IRIAQRCRELRNFSSLRAILSALQSNPIYRLKRSWGAVSREPLSTFRKLSQIFSDENNHL
                 541                                                      600 
   RalGDS  (515) LSRELLIKEGTSKFATLEMNPKRAQK-------RPKETGIIQGTVPYLGTFLTDLVMLDT
    RGL 1  (380) TSRELLMKEGTSKFANLDSSVKENQKRTQRRLQLQKDMGVMQGTVPYLGTFLTDLTMLDT
    RGL 2  (396) QSRELLVQEVKLQSPLEPHSKKAPRS-----------GSRGGGVVPYLGTFLKDLVMLDA
    RGL 3  (388) SSREILFQEEATEGSQEEDNTPGSLP-----------SKPPPGPVPYLGTFLTDLVMLDT
                 601                                                      660 
   RalGDS  (568) AMKDYLYGRLINFEKRRKEFEVIAQIKLLQSACNNYSIAPDEQFGAWFRAVERLSETESY
    RGL 1  (440) ALQDYIEGGLINFEKRRREFEVIAQIKLLQSACNSYCMTPDQKFIQWFQRQQLLTEEESY
    RGL 2  (445) ASKDELENGYINFDKRRKEFAVLSELRRLQNECRGYNLQPDHDIQRWLQGLRPLTEAQSH
    RGL 3  (437) ALPDMLEGDLINFEKRRKEWEILARIQQLQRRCQSYTLSPHPPILAALHAQNQLTEEQSY
                 661                                                      720 
   RalGDS  (628) NLSCELEPPSESASNTLRTKKNTAIVKRWSDRQAPSTELSTSGSSHSKSCDQLRCGPYLS
    RGL 1  (500) ALSCEIEAAADASTTSPKPRK--SMVKRLSLLFLGSDMITSP----TPTKEQPKSTASGS
    RGL 2  (505) RVSCEVEPPGSSDPPAPRVLRPTLVISQWTEVLGSVGVPTPLVS----------CDRPST
    RGL 3  (497) RLSRVIEPPAASCPSSPRIRRRISLTKRLSAKLAREKSSSPS----------------GS
                 721                                                      780 
   RalGDS  (688) SGDIADALSVHSAGSSSSDVEEINISFVPESPDG-QEKKFWESASQSSPETSGISSASSS
    RGL 1  (554) SGESMDSVSVSSCESNHSEAEEGSITPMDTPDEP-QKKLSESSSSCSSIHSMDTNSSGMS
    RGL 2  (555) GGDEAPTTPAPLLTRLAQHMKWPSVSSLDSALESSPSLHSPADPSHLSPPASSPRPSRGH
    RGL 3  (541) PGDPSSPTSSVSPGS------------PPSSP---RSRDAPAGSPPASPGPQGPSTKLPL
                 781                                                      840 
   RalGDS  (747) TSSSSASTTPVAATR--THKRSVSGLCNSSSALP-LYNQQVGDCCIIRVSLDVDN-GNMY
    RGL 1  (613) SLINPLSSPPSCNNNPKIHKRSVSVTSITSTVLPPVYNQQNEDTCIIRISVEDNN-GNMY
    RGL 2  (615) RRSASCGSPLSGGAEEASGGTGYGG----EGSGP-----GASDCRIIRVQMELGEDGSVY
    RGL 3  (586) SLDLPSPRPFALPLG--------------SPRIP-LPAQQSSEARVIRVSIDNDH-GNLY
93
                 841                                                      900 
   RalGDS  (803) KSILVTSQDKAPAVIRKAMDKHNLEEEEPEDYELLQILSDDRKLKIPENANVFYAMNSTA
    RGL 1  (672) KSIMLTSQDKTPAVIQRAMLKHNLDSDPAEEYELVQVISEDKELVIPDSANVFYAMNSQV
    RGL 2  (666) KSILVTSQDKAPSVISRVLKKNNRDSAVASEYELVQLLPGERELTIPASANVFYAMDGAS
    RGL 3  (630) RSILLTSQDKAPSVVRRALQKHNVPQPWACDYQLFQVLPGDRVLLIPDNANVFYAMSPVA
                 901                                                      960 
   RalGDS  (863) NYDFVLKKR----TFTKGVKVKHGASSTLPRMKQKG---------LKIAKGIF-------
    RGL 1  (732) NFDFILRKKN---SMEEQVKLRSRTSLTLPRTAKRGCWSNRHSK-ITLSRGPFEGKPIPN
    RGL 2  (726) -HDFLLRQRRRSSTATPGVTSGPSASGTPPSEGGGGSFPRIKATGRKIARALF-------
    RGL 3  (690) PRDFMLRRK--------EGTRNTLSVSPS-------------------------------
                 961           977 
   RalGDS  (903) ----------------- 
    RGL 1  (788) PLLGLDSTRTGHHHHHH 
    RGL 2  (778) ----------------- 
    RGL 3  (711) ----------------- 
